JP4915010B2 - 置換されたイソキノリン誘導体 - Google Patents
置換されたイソキノリン誘導体 Download PDFInfo
- Publication number
- JP4915010B2 JP4915010B2 JP2011519583A JP2011519583A JP4915010B2 JP 4915010 B2 JP4915010 B2 JP 4915010B2 JP 2011519583 A JP2011519583 A JP 2011519583A JP 2011519583 A JP2011519583 A JP 2011519583A JP 4915010 B2 JP4915010 B2 JP 4915010B2
- Authority
- JP
- Japan
- Prior art keywords
- ylsulfonyl
- isoquinoline
- group
- methyl
- diazepan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 192
- -1 1,4-diazepan-1-ylsulfonyl Chemical group 0.000 claims description 49
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 45
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 21
- 208000010412 Glaucoma Diseases 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000003282 alkyl amino group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 150000004280 isoquinoline-6-sulfonamides Chemical class 0.000 claims description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 9
- 208000028389 Nerve injury Diseases 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 230000008764 nerve damage Effects 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- MZLXYBXRZSNWBB-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)isoquinoline Chemical compound C=1C=C2C=NC=CC2=CC=1S(=O)(=O)N1CCCNCC1 MZLXYBXRZSNWBB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- BPQKTCHTDSFBRA-LBPRGKRZSA-N (3s)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-ol Chemical compound C1[C@@H](O)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 BPQKTCHTDSFBRA-LBPRGKRZSA-N 0.000 claims description 4
- XIOTVNFBSAMXJI-LBPRGKRZSA-N 5-methyl-6-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1C XIOTVNFBSAMXJI-LBPRGKRZSA-N 0.000 claims description 4
- JQCVNAPDICMXTI-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline Chemical compound CC1(C)CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JQCVNAPDICMXTI-UHFFFAOYSA-N 0.000 claims description 4
- RNEIMKVPLUHCHB-CYBMUJFWSA-N 6-[[(6r)-6-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C1CNC[C@H](C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 RNEIMKVPLUHCHB-CYBMUJFWSA-N 0.000 claims description 4
- TWSBSVWGUPOETO-GFCCVEGCSA-N 6-[[(7r)-7-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 TWSBSVWGUPOETO-GFCCVEGCSA-N 0.000 claims description 4
- ZUFZQYNHFCWKHK-CYBMUJFWSA-N 6-[[(7r)-7-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C1[C@H](C)CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 ZUFZQYNHFCWKHK-CYBMUJFWSA-N 0.000 claims description 4
- VWCRIWYLJNXKHS-LLVKDONJSA-N 7-fluoro-6-[[(2r)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCCN1S(=O)(=O)C1=CC2=CC=NC=C2C=C1F VWCRIWYLJNXKHS-LLVKDONJSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- FDYAKIUWSMKFGQ-UHFFFAOYSA-N methyl 1-isoquinolin-6-ylsulfonylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FDYAKIUWSMKFGQ-UHFFFAOYSA-N 0.000 claims description 4
- SOZPDCVLBLPLTM-ZDUSSCGKSA-N (3s)-1-isoquinolin-6-ylsulfonyl-n-methylpyrrolidin-3-amine Chemical compound C1[C@@H](NC)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 SOZPDCVLBLPLTM-ZDUSSCGKSA-N 0.000 claims description 3
- YVTXOUKOBNPJOS-INIZCTEOSA-N (3s)-n-butyl-1-isoquinolin-6-ylsulfonylpyrrolidin-3-amine Chemical compound C1[C@@H](NCCCC)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 YVTXOUKOBNPJOS-INIZCTEOSA-N 0.000 claims description 3
- HFQZKPFDQQPBRX-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)-2h-isoquinolin-1-one Chemical compound C=1C=C2C(=O)NC=CC2=CC=1S(=O)(=O)N1CCCNCC1 HFQZKPFDQQPBRX-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- NBMBEELYWJWDFE-GFCCVEGCSA-N (3r)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 NBMBEELYWJWDFE-GFCCVEGCSA-N 0.000 claims description 2
- GQUSOWGBCWSKJI-CYBMUJFWSA-N (5r)-4-isoquinolin-6-ylsulfonyl-5-methyl-1,4,7-oxadiazonane Chemical compound C[C@@H]1CNCCOCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 GQUSOWGBCWSKJI-CYBMUJFWSA-N 0.000 claims description 2
- UCPIBVHPKXKKJZ-OAHLLOKOSA-N 1-[(3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocan-1-yl]-2-(methylamino)ethanone Chemical compound C[C@@H]1CN(C(=O)CNC)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 UCPIBVHPKXKKJZ-OAHLLOKOSA-N 0.000 claims description 2
- IOCCFYZZIOHGTJ-UHFFFAOYSA-N 1-isoquinolin-6-ylsulfonylpiperidin-4-amine Chemical compound C1CC(N)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IOCCFYZZIOHGTJ-UHFFFAOYSA-N 0.000 claims description 2
- YETWNBFWWUILIX-CQSZACIVSA-N 2-[6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinolin-1-yl]sulfanylethanamine Chemical compound C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C(SCCN)=NC=C2)C2=C1 YETWNBFWWUILIX-CQSZACIVSA-N 0.000 claims description 2
- YUTYDFLBTQBWPM-ZDUSSCGKSA-N 2-[6-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinolin-1-yl]sulfanylethanamine Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C(SCCN)=NC=C2)C2=C1 YUTYDFLBTQBWPM-ZDUSSCGKSA-N 0.000 claims description 2
- LARGJMRXZPGWOV-CYBMUJFWSA-N 2-[6-[[(7r)-7-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinolin-1-yl]sulfanylethanamine Chemical compound C[C@@H]1CCNCCN1S(=O)(=O)C1=CC=C(C(SCCN)=NC=C2)C2=C1 LARGJMRXZPGWOV-CYBMUJFWSA-N 0.000 claims description 2
- ZHVMSVSBCDMGEU-UHFFFAOYSA-N 2-amino-1-(4-isoquinolin-6-ylsulfonyl-1,4-diazepan-1-yl)ethanone Chemical compound C1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 ZHVMSVSBCDMGEU-UHFFFAOYSA-N 0.000 claims description 2
- RVNYOUIDNQIXBW-CQSZACIVSA-N 2-amino-1-[(3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocan-1-yl]ethanone Chemical compound C[C@@H]1CN(C(=O)CN)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 RVNYOUIDNQIXBW-CQSZACIVSA-N 0.000 claims description 2
- SJZSDUJZGCKJIB-ZDUSSCGKSA-N 2-amino-1-[(3s)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazepan-1-yl]ethanone Chemical compound C[C@H]1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 SJZSDUJZGCKJIB-ZDUSSCGKSA-N 0.000 claims description 2
- LKIKGEWTSMVGGN-UHFFFAOYSA-N 5-bromo-6-(1,4-diazepan-1-ylsulfonyl)isoquinoline Chemical compound C1=CC2=CN=CC=C2C(Br)=C1S(=O)(=O)N1CCCNCC1 LKIKGEWTSMVGGN-UHFFFAOYSA-N 0.000 claims description 2
- YXNDSUSWOVMSIE-LLVKDONJSA-N 5-bromo-6-[[(2r)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br YXNDSUSWOVMSIE-LLVKDONJSA-N 0.000 claims description 2
- WXJJBGUBQYARTD-GFCCVEGCSA-N 5-bromo-6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br WXJJBGUBQYARTD-GFCCVEGCSA-N 0.000 claims description 2
- YXNDSUSWOVMSIE-NSHDSACASA-N 5-bromo-6-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br YXNDSUSWOVMSIE-NSHDSACASA-N 0.000 claims description 2
- PZSLKINVBOMHMZ-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)-5-phenylisoquinoline Chemical compound C=1C=C2C=NC=CC2=C(C=2C=CC=CC=2)C=1S(=O)(=O)N1CCCNCC1 PZSLKINVBOMHMZ-UHFFFAOYSA-N 0.000 claims description 2
- BBTHMYXPZFPCKF-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)-8-fluoroisoquinoline Chemical compound C=1C2=CC=NC=C2C(F)=CC=1S(=O)(=O)N1CCCNCC1 BBTHMYXPZFPCKF-UHFFFAOYSA-N 0.000 claims description 2
- VAZADNNCUUOFMT-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)isoquinolin-1-amine Chemical compound C=1C=C2C(N)=NC=CC2=CC=1S(=O)(=O)N1CCCNCC1 VAZADNNCUUOFMT-UHFFFAOYSA-N 0.000 claims description 2
- LQYKUBKUSFWBEE-UHFFFAOYSA-N 6-(1,4-diazocan-1-ylsulfonyl)isoquinoline Chemical compound C=1C=C2C=NC=CC2=CC=1S(=O)(=O)N1CCCCNCC1 LQYKUBKUSFWBEE-UHFFFAOYSA-N 0.000 claims description 2
- YVVCCEBQGOKCSR-VXGBXAGGSA-N 6-[(2r,6r)-2,6-dimethylpiperazin-1-yl]sulfonylisoquinoline Chemical compound C[C@@H]1CNC[C@@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 YVVCCEBQGOKCSR-VXGBXAGGSA-N 0.000 claims description 2
- OJBYZEFOQUURLD-NSHDSACASA-N 6-[(2s)-2-methylpiperazin-1-yl]sulfonylisoquinoline Chemical compound C[C@H]1CNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OJBYZEFOQUURLD-NSHDSACASA-N 0.000 claims description 2
- PSJHTVRIXJJVLR-UHFFFAOYSA-N 6-[(3-methyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline Chemical compound C1CCNC(C)CN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 PSJHTVRIXJJVLR-UHFFFAOYSA-N 0.000 claims description 2
- TWSBSVWGUPOETO-UHFFFAOYSA-N 6-[(7-methyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline Chemical compound CC1CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 TWSBSVWGUPOETO-UHFFFAOYSA-N 0.000 claims description 2
- URFKQCIAXWVKNV-STQMWFEESA-N 6-[[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]sulfonyl]isoquinoline Chemical compound C1=NC=CC2=CC(S(=O)(=O)N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 URFKQCIAXWVKNV-STQMWFEESA-N 0.000 claims description 2
- NHJCRLTZQNNTLF-OAHLLOKOSA-N 6-[[(2r)-2-ethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound CC[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 NHJCRLTZQNNTLF-OAHLLOKOSA-N 0.000 claims description 2
- KMCKLBWZUUKHGU-MRXNPFEDSA-N 6-[[(2r)-2-ethyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound CC[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 KMCKLBWZUUKHGU-MRXNPFEDSA-N 0.000 claims description 2
- VLVRABMZGXWZKG-CYBMUJFWSA-N 6-[[(2r)-2-methyl-1,4,7-triazonan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 VLVRABMZGXWZKG-CYBMUJFWSA-N 0.000 claims description 2
- XYYOGLGFYXNUNF-GFCCVEGCSA-N 6-[[(2r)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XYYOGLGFYXNUNF-GFCCVEGCSA-N 0.000 claims description 2
- VTWVDHSKSBSZFZ-GFCCVEGCSA-N 6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]-5-nitroisoquinoline Chemical compound C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1[N+]([O-])=O VTWVDHSKSBSZFZ-GFCCVEGCSA-N 0.000 claims description 2
- OIJDBECSPSHUGA-CYBMUJFWSA-N 6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OIJDBECSPSHUGA-CYBMUJFWSA-N 0.000 claims description 2
- VTMGASIHJBYVTO-CQSZACIVSA-N 6-[[(2r)-2-methyl-1,4-diazonan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNCCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 VTMGASIHJBYVTO-CQSZACIVSA-N 0.000 claims description 2
- IWRQNOLQHDBIRY-CYBMUJFWSA-N 6-[[(2r)-2-methyl-1,5-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CCNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IWRQNOLQHDBIRY-CYBMUJFWSA-N 0.000 claims description 2
- OAFPFDAKMOGNGG-CHWSQXEVSA-N 6-[[(2r,7r)-2,7-dimethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CCNC[C@@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OAFPFDAKMOGNGG-CHWSQXEVSA-N 0.000 claims description 2
- HRMBNEORRZITCK-CQSZACIVSA-N 6-[[(2s)-2-(fluoromethyl)-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound FC[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 HRMBNEORRZITCK-CQSZACIVSA-N 0.000 claims description 2
- IFFSHQGJCMSUDV-OAHLLOKOSA-N 6-[[(2s)-2-(fluoromethyl)-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound FC[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IFFSHQGJCMSUDV-OAHLLOKOSA-N 0.000 claims description 2
- XYYOGLGFYXNUNF-LBPRGKRZSA-N 6-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XYYOGLGFYXNUNF-LBPRGKRZSA-N 0.000 claims description 2
- OIJDBECSPSHUGA-ZDUSSCGKSA-N 6-[[(2s)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OIJDBECSPSHUGA-ZDUSSCGKSA-N 0.000 claims description 2
- VTMGASIHJBYVTO-AWEZNQCLSA-N 6-[[(2s)-2-methyl-1,4-diazonan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CNCCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 VTMGASIHJBYVTO-AWEZNQCLSA-N 0.000 claims description 2
- IWRQNOLQHDBIRY-ZDUSSCGKSA-N 6-[[(2s)-2-methyl-1,5-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CCNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IWRQNOLQHDBIRY-ZDUSSCGKSA-N 0.000 claims description 2
- OAFPFDAKMOGNGG-OLZOCXBDSA-N 6-[[(2s,7r)-2,7-dimethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CCNC[C@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OAFPFDAKMOGNGG-OLZOCXBDSA-N 0.000 claims description 2
- OAFPFDAKMOGNGG-STQMWFEESA-N 6-[[(2s,7s)-2,7-dimethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CCNC[C@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OAFPFDAKMOGNGG-STQMWFEESA-N 0.000 claims description 2
- TWSBSVWGUPOETO-LBPRGKRZSA-N 6-[[(7s)-7-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@H]1CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 TWSBSVWGUPOETO-LBPRGKRZSA-N 0.000 claims description 2
- UAZLRZHRADFSOO-CYBMUJFWSA-N 6-[[(8r)-8-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CCCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 UAZLRZHRADFSOO-CYBMUJFWSA-N 0.000 claims description 2
- WHMCRCAGUJBDJR-UHFFFAOYSA-N 6-piperazin-1-ylsulfonylisoquinoline Chemical compound C=1C=C2C=NC=CC2=CC=1S(=O)(=O)N1CCNCC1 WHMCRCAGUJBDJR-UHFFFAOYSA-N 0.000 claims description 2
- FIEFQBWJTAWTIV-UHFFFAOYSA-N isoquinoline-6-sulfonamide Chemical class C1=NC=CC2=CC(S(=O)(=O)N)=CC=C21 FIEFQBWJTAWTIV-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 224
- 238000003786 synthesis reaction Methods 0.000 description 224
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 172
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- 238000004519 manufacturing process Methods 0.000 description 104
- 239000000243 solution Substances 0.000 description 79
- 238000006243 chemical reaction Methods 0.000 description 77
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 74
- YPRGBDMKXDUHGQ-HNNXBMFYSA-N tert-butyl (3s)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazepane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 YPRGBDMKXDUHGQ-HNNXBMFYSA-N 0.000 description 47
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 41
- 238000002844 melting Methods 0.000 description 36
- 230000008018 melting Effects 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 239000012230 colorless oil Substances 0.000 description 31
- 239000012043 crude product Substances 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
- 238000010898 silica gel chromatography Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000002178 crystalline material Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 26
- 238000001914 filtration Methods 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 21
- 230000009471 action Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 229940125773 compound 10 Drugs 0.000 description 18
- IYRMNDOLPONSCJ-UHFFFAOYSA-N isoquinolin-2-ium;chloride Chemical compound Cl.C1=NC=CC2=CC=CC=C21 IYRMNDOLPONSCJ-UHFFFAOYSA-N 0.000 description 18
- 229940125782 compound 2 Drugs 0.000 description 17
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- QMAWUKHLNJCSSG-UHFFFAOYSA-N tert-butyl 4-isoquinolin-6-ylsulfonylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 QMAWUKHLNJCSSG-UHFFFAOYSA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- XXTSRBOWLYHWPP-LTCKWSDVSA-N 6-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XXTSRBOWLYHWPP-LTCKWSDVSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 208000020431 spinal cord injury Diseases 0.000 description 10
- DWDKNCBAMTZHPM-UHFFFAOYSA-N 1-isoquinolin-6-ylsulfonylpiperidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 DWDKNCBAMTZHPM-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 9
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 229940125878 compound 36 Drugs 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 0 ***N(*)S(c1cc2ccncc2cc1)(=O)=O Chemical compound ***N(*)S(c1cc2ccncc2cc1)(=O)=O 0.000 description 7
- SCIVXCIPKRLLBG-NJHZPMQHSA-N 6-[[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C1=NC=CC2=CC(S(=O)(=O)N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 SCIVXCIPKRLLBG-NJHZPMQHSA-N 0.000 description 7
- HLGPSMFSBILZNA-MPWMAQOGSA-N 6-[[(3r,6z)-3-methyl-2,3,5,8-tetrahydro-1h-1,4-diazocin-4-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNC\C=C/CN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 HLGPSMFSBILZNA-MPWMAQOGSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940125833 compound 23 Drugs 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000004410 intraocular pressure Effects 0.000 description 7
- KWADYKRPIUHOTO-UHFFFAOYSA-N isoquinoline-6-sulfonyl chloride Chemical compound C1=NC=CC2=CC(S(=O)(=O)Cl)=CC=C21 KWADYKRPIUHOTO-UHFFFAOYSA-N 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 6
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 210000003050 axon Anatomy 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 5
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 5
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 5
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 5
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 5
- XQQGLGYZBHWKLZ-XJCLVHIMSA-N 2-[6-[[(2R)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinolin-1-yl]sulfanylethanamine trihydrochloride Chemical compound Cl.Cl.Cl.C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C(SCCN)=NC=C2)C2=C1 XQQGLGYZBHWKLZ-XJCLVHIMSA-N 0.000 description 5
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 5
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 5
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 5
- PZNYXUBNTDLOMX-FCQHKQNSSA-N 4-[(2S)-1-isoquinolin-6-ylsulfonyl-1,4-diazepan-2-yl]butan-1-amine trihydrochloride Chemical compound Cl.Cl.Cl.NCCCC[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 PZNYXUBNTDLOMX-FCQHKQNSSA-N 0.000 description 5
- IMTVTPPTBAAONQ-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)-8-fluoroisoquinoline;dihydrochloride Chemical compound Cl.Cl.C=1C2=CC=NC=C2C(F)=CC=1S(=O)(=O)N1CCCNCC1 IMTVTPPTBAAONQ-UHFFFAOYSA-N 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 5
- 229940126657 Compound 17 Drugs 0.000 description 5
- 229940126639 Compound 33 Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 5
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 5
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000007810 chemical reaction solvent Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229940126543 compound 14 Drugs 0.000 description 5
- 229940125758 compound 15 Drugs 0.000 description 5
- 229940126142 compound 16 Drugs 0.000 description 5
- 229940125810 compound 20 Drugs 0.000 description 5
- 229940126086 compound 21 Drugs 0.000 description 5
- 229940125961 compound 24 Drugs 0.000 description 5
- 229940125846 compound 25 Drugs 0.000 description 5
- 229940125851 compound 27 Drugs 0.000 description 5
- 229940127204 compound 29 Drugs 0.000 description 5
- 229940125877 compound 31 Drugs 0.000 description 5
- 229940125807 compound 37 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- NGFCTYXFMDWFRQ-UHFFFAOYSA-N isoquinolin-6-amine Chemical compound C1=NC=CC2=CC(N)=CC=C21 NGFCTYXFMDWFRQ-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000004531 blood pressure lowering effect Effects 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126208 compound 22 Drugs 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
- OGSUNARYWRKBHH-UHFFFAOYSA-N tert-butyl 4-(2-oxidoisoquinolin-2-ium-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=[N+]([O-])C=C2)C2=C1 OGSUNARYWRKBHH-UHFFFAOYSA-N 0.000 description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- KSHARUQDBWSRFQ-GXKRWWSZSA-N 6-[[(2s)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 KSHARUQDBWSRFQ-GXKRWWSZSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 229940127271 compound 49 Drugs 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- SZIRRVNKZVNGND-AWEZNQCLSA-N tert-butyl (3s)-4-(5-bromoisoquinolin-6-yl)sulfonyl-3-methyl-1,4-diazepane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br SZIRRVNKZVNGND-AWEZNQCLSA-N 0.000 description 3
- YFFIJRMANQVNCF-KRWDZBQOSA-N tert-butyl (3s)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazonane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 YFFIJRMANQVNCF-KRWDZBQOSA-N 0.000 description 3
- XWWXBSCTKRKJDN-UHFFFAOYSA-N tert-butyl 4-isoquinolin-6-ylsulfonyl-5-methyl-1,4-diazepane-1-carboxylate Chemical compound CC1CCN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XWWXBSCTKRKJDN-UHFFFAOYSA-N 0.000 description 3
- MOYXSDAIINVYRP-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)-n-[2-methyl-2-(phenylmethoxycarbonylamino)propyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CCCO)CC(C)(C)NC(=O)OCC1=CC=CC=C1 MOYXSDAIINVYRP-UHFFFAOYSA-N 0.000 description 3
- BTJKWRBVNYILMX-HNNXBMFYSA-N tert-butyl n-[(3s)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 BTJKWRBVNYILMX-HNNXBMFYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- QNBGSARJPUJLSJ-CURYUGHLSA-N (3r)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1[C@H](N)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 QNBGSARJPUJLSJ-CURYUGHLSA-N 0.000 description 2
- XASVLVZBYVVJBL-GXKRWWSZSA-N (3s)-1-isoquinolin-6-ylsulfonyl-n-methylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](NC)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XASVLVZBYVVJBL-GXKRWWSZSA-N 0.000 description 2
- UUUQCSHMORHURW-YDALLXLXSA-N (3s)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-ol;hydrochloride Chemical compound Cl.C1[C@@H](O)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 UUUQCSHMORHURW-YDALLXLXSA-N 0.000 description 2
- IXGMSGLBMXLPHV-SQKCAUCHSA-N (3s)-n-butyl-1-isoquinolin-6-ylsulfonylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](NCCCC)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IXGMSGLBMXLPHV-SQKCAUCHSA-N 0.000 description 2
- GXOOZHCPFAHWHN-FFXKMJQXSA-N (5r)-4-isoquinolin-6-ylsulfonyl-5-methyl-1,4,7-oxadiazonane;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCOCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 GXOOZHCPFAHWHN-FFXKMJQXSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- CPMNVJPJVXRHHB-QCUBGVIVSA-N 1-[(3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocan-1-yl]-2-(methylamino)ethanone;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CN(C(=O)CNC)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 CPMNVJPJVXRHHB-QCUBGVIVSA-N 0.000 description 2
- CXMPAAGZYZLINQ-JEZXJMRTSA-N 2-[6-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinolin-1-yl]sulfanylethanamine trihydrochloride Chemical compound Cl.Cl.Cl.C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C(SCCN)=NC=C2)C2=C1 CXMPAAGZYZLINQ-JEZXJMRTSA-N 0.000 description 2
- MZOVJKXLHYPIOE-BXUUEFRQSA-N 2-[6-[[(7R)-7-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinolin-1-yl]sulfanylethanamine trihydrochloride Chemical compound Cl.Cl.Cl.C[C@@H]1CCNCCN1S(=O)(=O)C1=CC=C(C(SCCN)=NC=C2)C2=C1 MZOVJKXLHYPIOE-BXUUEFRQSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- VXJVJPFASIMZBL-UHFFFAOYSA-N 2-amino-1-(4-isoquinolin-6-ylsulfonyl-1,4-diazepan-1-yl)ethanone;dihydrochloride Chemical compound Cl.Cl.C1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 VXJVJPFASIMZBL-UHFFFAOYSA-N 0.000 description 2
- JWCIGORCFVQOEF-FMOMHUKBSA-N 2-amino-1-[(3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocan-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CN(C(=O)CN)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JWCIGORCFVQOEF-FMOMHUKBSA-N 0.000 description 2
- MWMIKRNUQRIBMW-GXKRWWSZSA-N 2-amino-1-[(3s)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazepan-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 MWMIKRNUQRIBMW-GXKRWWSZSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZHGQODYTINZURO-NVJADKKVSA-N 5-bromo-6-[[(2r)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br ZHGQODYTINZURO-NVJADKKVSA-N 0.000 description 2
- QHNLRFREFYZRIP-CURYUGHLSA-N 5-bromo-6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br QHNLRFREFYZRIP-CURYUGHLSA-N 0.000 description 2
- ZHGQODYTINZURO-IDMXKUIJSA-N 5-bromo-6-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br ZHGQODYTINZURO-IDMXKUIJSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- ZFTMTDNUNGXFLA-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)-5-phenylisoquinoline;dihydrochloride Chemical compound Cl.Cl.C=1C=C2C=NC=CC2=C(C=2C=CC=CC=2)C=1S(=O)(=O)N1CCCNCC1 ZFTMTDNUNGXFLA-UHFFFAOYSA-N 0.000 description 2
- DLNDVPFKEAPGEL-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)isoquinolin-1-amine;dihydrochloride Chemical compound Cl.Cl.C=1C=C2C(N)=NC=CC2=CC=1S(=O)(=O)N1CCCNCC1 DLNDVPFKEAPGEL-UHFFFAOYSA-N 0.000 description 2
- PQWTWBFOYOYOLJ-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)isoquinoline;dihydrochloride Chemical compound Cl.Cl.C=1C=C2C=NC=CC2=CC=1S(=O)(=O)N1CCCNCC1 PQWTWBFOYOYOLJ-UHFFFAOYSA-N 0.000 description 2
- CEJLIGWESRWTQB-UHFFFAOYSA-N 6-(1,4-diazocan-1-ylsulfonyl)isoquinoline;dihydrochloride Chemical compound Cl.Cl.C=1C=C2C=NC=CC2=CC=1S(=O)(=O)N1CCCCNCC1 CEJLIGWESRWTQB-UHFFFAOYSA-N 0.000 description 2
- AUYKOUVMDOIDII-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.CC1(C)CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 AUYKOUVMDOIDII-UHFFFAOYSA-N 0.000 description 2
- VYHCIDYOHBRWDX-MBORUXJMSA-N 6-[(2r,6r)-2,6-dimethylpiperazin-1-yl]sulfonylisoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNC[C@@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 VYHCIDYOHBRWDX-MBORUXJMSA-N 0.000 description 2
- JGQNQTBTOGTWPD-IDMXKUIJSA-N 6-[(2s)-2-methylpiperazin-1-yl]sulfonylisoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JGQNQTBTOGTWPD-IDMXKUIJSA-N 0.000 description 2
- WXGWAYSYCIYUSG-UHFFFAOYSA-N 6-[(3-methyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C1CCNC(C)CN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 WXGWAYSYCIYUSG-UHFFFAOYSA-N 0.000 description 2
- QEQGAYLACCTBQH-UHFFFAOYSA-N 6-[(7-methyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.CC1CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 QEQGAYLACCTBQH-UHFFFAOYSA-N 0.000 description 2
- GJCAKLRTVAEWEE-BXUUEFRQSA-N 6-[[(2R)-2-methyl-1,4,7-triazonan-1-yl]sulfonyl]isoquinoline trihydrochloride Chemical compound Cl.Cl.Cl.C[C@@H]1CNCCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 GJCAKLRTVAEWEE-BXUUEFRQSA-N 0.000 description 2
- KUFVSBHMTVSFPA-CKUXDGONSA-N 6-[[(2r)-2-(fluoromethyl)-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.FC[C@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 KUFVSBHMTVSFPA-CKUXDGONSA-N 0.000 description 2
- JEKLEILGSFNAIN-QCUBGVIVSA-N 6-[[(2r)-2-ethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.CC[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JEKLEILGSFNAIN-QCUBGVIVSA-N 0.000 description 2
- RGXOCHQBRQONSQ-GGMCWBHBSA-N 6-[[(2r)-2-ethyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.CC[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 RGXOCHQBRQONSQ-GGMCWBHBSA-N 0.000 description 2
- XXTSRBOWLYHWPP-CURYUGHLSA-N 6-[[(2r)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XXTSRBOWLYHWPP-CURYUGHLSA-N 0.000 description 2
- KVKLOJSJRVRHTH-CURYUGHLSA-N 6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]-5-nitroisoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1[N+]([O-])=O KVKLOJSJRVRHTH-CURYUGHLSA-N 0.000 description 2
- KSHARUQDBWSRFQ-FFXKMJQXSA-N 6-[[(2r)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 KSHARUQDBWSRFQ-FFXKMJQXSA-N 0.000 description 2
- FQRZEKXKIORLLZ-FMOMHUKBSA-N 6-[[(2r)-2-methyl-1,4-diazonan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FQRZEKXKIORLLZ-FMOMHUKBSA-N 0.000 description 2
- IHDCHCYFIYEJMM-FFXKMJQXSA-N 6-[[(2r)-2-methyl-1,5-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CCNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IHDCHCYFIYEJMM-FFXKMJQXSA-N 0.000 description 2
- FNTDUKWFZOWNNC-SNFSYSBXSA-N 6-[[(2r,7r)-2,7-dimethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CCNC[C@@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FNTDUKWFZOWNNC-SNFSYSBXSA-N 0.000 description 2
- CQQXXWFSQGOCCW-FMOMHUKBSA-N 6-[[(2s)-2-(fluoromethyl)-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.FC[C@@H]1CNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 CQQXXWFSQGOCCW-FMOMHUKBSA-N 0.000 description 2
- IHDCHCYFIYEJMM-GXKRWWSZSA-N 6-[[(2s)-2-methyl-1,5-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CCNCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IHDCHCYFIYEJMM-GXKRWWSZSA-N 0.000 description 2
- FNTDUKWFZOWNNC-VAALMUBNSA-N 6-[[(2s,7r)-2,7-dimethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CCNC[C@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FNTDUKWFZOWNNC-VAALMUBNSA-N 0.000 description 2
- FNTDUKWFZOWNNC-NJHZPMQHSA-N 6-[[(2s,7s)-2,7-dimethyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CCNC[C@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FNTDUKWFZOWNNC-NJHZPMQHSA-N 0.000 description 2
- IWQBPDDGQPWCNU-XQJDBVBESA-N 6-[[(3r,6z)-3-methyl-2,3,5,8-tetrahydro-1h-1,4-diazocin-4-yl]sulfonyl]isoquinoline Chemical compound C[C@@H]1CNC\C=C/CN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 IWQBPDDGQPWCNU-XQJDBVBESA-N 0.000 description 2
- AZMOVGYFKXENGE-FFXKMJQXSA-N 6-[[(6r)-6-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C1CNC[C@H](C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 AZMOVGYFKXENGE-FFXKMJQXSA-N 0.000 description 2
- QEQGAYLACCTBQH-CURYUGHLSA-N 6-[[(7r)-7-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 QEQGAYLACCTBQH-CURYUGHLSA-N 0.000 description 2
- NQSZREWZSUQHNL-FFXKMJQXSA-N 6-[[(7r)-7-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C1[C@H](C)CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 NQSZREWZSUQHNL-FFXKMJQXSA-N 0.000 description 2
- QEQGAYLACCTBQH-LTCKWSDVSA-N 6-[[(7s)-7-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 QEQGAYLACCTBQH-LTCKWSDVSA-N 0.000 description 2
- OAAIIAXNZCCBRB-FFXKMJQXSA-N 6-[[(8r)-8-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CCCNCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OAAIIAXNZCCBRB-FFXKMJQXSA-N 0.000 description 2
- ZTEATMVVGQUULZ-UHFFFAOYSA-N 6-bromoisoquinoline Chemical compound C1=NC=CC2=CC(Br)=CC=C21 ZTEATMVVGQUULZ-UHFFFAOYSA-N 0.000 description 2
- WMDWLSKCICLMLB-UHFFFAOYSA-N 6-piperazin-1-ylsulfonylisoquinoline;dihydrochloride Chemical compound Cl.Cl.C=1C=C2C=NC=CC2=CC=1S(=O)(=O)N1CCNCC1 WMDWLSKCICLMLB-UHFFFAOYSA-N 0.000 description 2
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 2
- VLTVZTMIIGXSIT-NVJADKKVSA-N 7-fluoro-6-[[(2r)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CNCCCN1S(=O)(=O)C1=CC2=CC=NC=C2C=C1F VLTVZTMIIGXSIT-NVJADKKVSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- CXMLBZXMMMIGES-UHFFFAOYSA-N benzyl n-(1-hydroxy-2-methylpropan-2-yl)carbamate Chemical compound OCC(C)(C)NC(=O)OCC1=CC=CC=C1 CXMLBZXMMMIGES-UHFFFAOYSA-N 0.000 description 2
- DNFWFQPRWSKKDA-UHFFFAOYSA-N benzyl n-(2-methyl-1-oxopropan-2-yl)carbamate Chemical compound O=CC(C)(C)NC(=O)OCC1=CC=CC=C1 DNFWFQPRWSKKDA-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- FJEVBCSEOZTWTF-LJQANCHMSA-N ditert-butyl (6r)-7-isoquinolin-6-ylsulfonyl-6-methyl-1,4,7-triazonane-1,4-dicarboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FJEVBCSEOZTWTF-LJQANCHMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- NLUDICPCKPZJOC-UHFFFAOYSA-N methyl 1-isoquinolin-6-ylsulfonylpiperidine-4-carboxylate;hydrochloride Chemical compound Cl.C1CC(C(=O)OC)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 NLUDICPCKPZJOC-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FMZXOPYJCQMAKL-WWQCOOJYSA-N tert-butyl (2r,6z)-2-methyl-2,3,5,8-tetrahydro-1h-1,4-diazocine-4-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)C\C=C/CN1 FMZXOPYJCQMAKL-WWQCOOJYSA-N 0.000 description 2
- OKRHCCKZVVZLGW-GOSISDBHSA-N tert-butyl (3r)-3-ethyl-4-isoquinolin-6-ylsulfonyl-1,4-diazepane-1-carboxylate Chemical compound CC[C@@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OKRHCCKZVVZLGW-GOSISDBHSA-N 0.000 description 2
- DARBVIVOPAYJEL-LJQANCHMSA-N tert-butyl (3r)-3-ethyl-4-isoquinolin-6-ylsulfonyl-1,4-diazocane-1-carboxylate Chemical compound CC[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 DARBVIVOPAYJEL-LJQANCHMSA-N 0.000 description 2
- MFULALVZTNAYMI-OAHLLOKOSA-N tert-butyl (3r)-3-methyl-4-(5-nitroisoquinolin-6-yl)sulfonyl-1,4-diazocane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1[N+]([O-])=O MFULALVZTNAYMI-OAHLLOKOSA-N 0.000 description 2
- OAXCFWUDRNBTOR-HXUWFJFHSA-N tert-butyl (3r)-3-methyl-4-[1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylsulfanyl]isoquinolin-6-yl]sulfonyl-1,4-diazocane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C(SCCNC(=O)OC(C)(C)C)=NC=C2)C2=C1 OAXCFWUDRNBTOR-HXUWFJFHSA-N 0.000 description 2
- SZIRRVNKZVNGND-CQSZACIVSA-N tert-butyl (3r)-4-(5-bromoisoquinolin-6-yl)sulfonyl-3-methyl-1,4-diazepane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br SZIRRVNKZVNGND-CQSZACIVSA-N 0.000 description 2
- ZINDKHBAJIRXPM-OAHLLOKOSA-N tert-butyl (3r)-4-(5-bromoisoquinolin-6-yl)sulfonyl-3-methyl-1,4-diazocane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br ZINDKHBAJIRXPM-OAHLLOKOSA-N 0.000 description 2
- YPRGBDMKXDUHGQ-OAHLLOKOSA-N tert-butyl (3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazepane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 YPRGBDMKXDUHGQ-OAHLLOKOSA-N 0.000 description 2
- LWRDPGHBTXAGJR-MRXNPFEDSA-N tert-butyl (3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 LWRDPGHBTXAGJR-MRXNPFEDSA-N 0.000 description 2
- YFFIJRMANQVNCF-QGZVFWFLSA-N tert-butyl (3r)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazonane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 YFFIJRMANQVNCF-QGZVFWFLSA-N 0.000 description 2
- ZSKFWXVONIYMJU-HZPDHXFCSA-N tert-butyl (3r,5r)-4-isoquinolin-6-ylsulfonyl-3,5-dimethyl-1,4-diazepane-1-carboxylate Chemical compound C[C@@H]1CCN(C(=O)OC(C)(C)C)C[C@@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 ZSKFWXVONIYMJU-HZPDHXFCSA-N 0.000 description 2
- KTAZGCGXECDCSG-HUUCEWRRSA-N tert-butyl (3r,5r)-4-isoquinolin-6-ylsulfonyl-3,5-dimethylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 KTAZGCGXECDCSG-HUUCEWRRSA-N 0.000 description 2
- ZVVHPFNMMJAZJB-QGZVFWFLSA-N tert-butyl (3s)-3-(fluoromethyl)-4-isoquinolin-6-ylsulfonyl-1,4-diazepane-1-carboxylate Chemical compound FC[C@@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 ZVVHPFNMMJAZJB-QGZVFWFLSA-N 0.000 description 2
- LNFJRMAMZOUODO-GOSISDBHSA-N tert-butyl (3s)-3-(fluoromethyl)-4-isoquinolin-6-ylsulfonyl-1,4-diazocane-1-carboxylate Chemical compound FC[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 LNFJRMAMZOUODO-GOSISDBHSA-N 0.000 description 2
- VJVVSHVHSDDDIL-HNNXBMFYSA-N tert-butyl (3s)-3-methyl-4-(2-oxidoisoquinolin-2-ium-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=[N+]([O-])C=C2)C2=C1 VJVVSHVHSDDDIL-HNNXBMFYSA-N 0.000 description 2
- CPJSCSLSDDWOAE-HNNXBMFYSA-N tert-butyl (3s)-3-methyl-4-(5-methylisoquinolin-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1C CPJSCSLSDDWOAE-HNNXBMFYSA-N 0.000 description 2
- IYFFKSZYUIIAQA-IBGZPJMESA-N tert-butyl (3s)-3-methyl-4-[1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylsulfanyl]isoquinolin-6-yl]sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C(SCCNC(=O)OC(C)(C)C)=NC=C2)C2=C1 IYFFKSZYUIIAQA-IBGZPJMESA-N 0.000 description 2
- JUKNSXSAKUOYTC-QHCPKHFHSA-N tert-butyl (3s)-4-isoquinolin-6-ylsulfonyl-3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]-1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NCCCC[C@H]1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JUKNSXSAKUOYTC-QHCPKHFHSA-N 0.000 description 2
- LWRDPGHBTXAGJR-INIZCTEOSA-N tert-butyl (3s)-4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocane-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 LWRDPGHBTXAGJR-INIZCTEOSA-N 0.000 description 2
- JELUYWOUAZDUMU-AWEZNQCLSA-N tert-butyl (3s)-4-isoquinolin-6-ylsulfonyl-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JELUYWOUAZDUMU-AWEZNQCLSA-N 0.000 description 2
- ZSKFWXVONIYMJU-CVEARBPZSA-N tert-butyl (3s,5r)-4-isoquinolin-6-ylsulfonyl-3,5-dimethyl-1,4-diazepane-1-carboxylate Chemical compound C[C@@H]1CCN(C(=O)OC(C)(C)C)C[C@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 ZSKFWXVONIYMJU-CVEARBPZSA-N 0.000 description 2
- ZSKFWXVONIYMJU-HOTGVXAUSA-N tert-butyl (3s,5s)-4-isoquinolin-6-ylsulfonyl-3,5-dimethyl-1,4-diazepane-1-carboxylate Chemical compound C[C@H]1CCN(C(=O)OC(C)(C)C)C[C@H](C)N1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 ZSKFWXVONIYMJU-HOTGVXAUSA-N 0.000 description 2
- HELFZYYPXYAJNE-NYRJJRHWSA-N tert-butyl (4r)-5-isoquinolin-6-ylsulfonyl-4-methyl-1,5-diazocane-2-carboxylate Chemical compound C[C@@H]1CC(C(=O)OC(C)(C)C)NCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 HELFZYYPXYAJNE-NYRJJRHWSA-N 0.000 description 2
- HELFZYYPXYAJNE-FUKCDUGKSA-N tert-butyl (4s)-5-isoquinolin-6-ylsulfonyl-4-methyl-1,5-diazocane-2-carboxylate Chemical compound C[C@H]1CC(C(=O)OC(C)(C)C)NCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 HELFZYYPXYAJNE-FUKCDUGKSA-N 0.000 description 2
- JWAUQXXLZFLYEP-MRXNPFEDSA-N tert-butyl (5r)-4-isoquinolin-6-ylsulfonyl-5-methyl-1,4-diazocane-1-carboxylate Chemical compound C[C@@H]1CCCN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 JWAUQXXLZFLYEP-MRXNPFEDSA-N 0.000 description 2
- JZQAHHCJWKHLJX-LJQANCHMSA-N tert-butyl (5r)-5-methyl-4-[1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylsulfanyl]isoquinolin-6-yl]sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C[C@@H]1CCN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C(SCCNC(=O)OC(C)(C)C)=NC=C2)C2=C1 JZQAHHCJWKHLJX-LJQANCHMSA-N 0.000 description 2
- MOAADGSWEQLGHH-MRXNPFEDSA-N tert-butyl (6r)-7-isoquinolin-6-ylsulfonyl-6-methyl-1,4,7-oxadiazonane-4-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCOCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 MOAADGSWEQLGHH-MRXNPFEDSA-N 0.000 description 2
- GJHULFBVBTYLIX-UHFFFAOYSA-N tert-butyl 4-(1-aminoisoquinolin-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C(N)=NC=C2)C2=C1 GJHULFBVBTYLIX-UHFFFAOYSA-N 0.000 description 2
- FXLCQDZHFRZXFQ-UHFFFAOYSA-N tert-butyl 4-(1-methoxyisoquinolin-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C=1C=C2C(OC)=NC=CC2=CC=1S(=O)(=O)N1CCCN(C(=O)OC(C)(C)C)CC1 FXLCQDZHFRZXFQ-UHFFFAOYSA-N 0.000 description 2
- KUVKIDXGKUGFEI-UHFFFAOYSA-N tert-butyl 4-(5-phenylisoquinolin-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1C1=CC=CC=C1 KUVKIDXGKUGFEI-UHFFFAOYSA-N 0.000 description 2
- MQKANASLWZLFSO-UHFFFAOYSA-N tert-butyl 4-isoquinolin-6-ylsulfonyl-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 MQKANASLWZLFSO-UHFFFAOYSA-N 0.000 description 2
- KMIVQVHIRYAEII-UHFFFAOYSA-N tert-butyl 4-isoquinolin-6-ylsulfonyl-1,4-diazocane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 KMIVQVHIRYAEII-UHFFFAOYSA-N 0.000 description 2
- PDOUCEARVXSCFY-UHFFFAOYSA-N tert-butyl 4-isoquinolin-6-ylsulfonyl-2-methyl-1,4-diazepane-1-carboxylate Chemical compound C1CCN(C(=O)OC(C)(C)C)C(C)CN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 PDOUCEARVXSCFY-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- OQGHRLCOQRKPPR-UHFFFAOYSA-N tert-butyl n-(1-isoquinolin-6-ylsulfonylpiperidin-4-yl)carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 OQGHRLCOQRKPPR-UHFFFAOYSA-N 0.000 description 2
- WZYOFGDVJLOENE-UHFFFAOYSA-N tert-butyl n-(2-amino-2-methylpropyl)-n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CC(C)(C)N)CCCO WZYOFGDVJLOENE-UHFFFAOYSA-N 0.000 description 2
- PAMKHEQSBXZUOZ-MRXNPFEDSA-N tert-butyl n-(2-hydroxyethyl)-n-[(2r)-4-(isoquinolin-6-ylsulfonylamino)-2-methylbutyl]carbamate Chemical compound C1=NC=CC2=CC(S(=O)(=O)NCC[C@@H](C)CN(CCO)C(=O)OC(C)(C)C)=CC=C21 PAMKHEQSBXZUOZ-MRXNPFEDSA-N 0.000 description 2
- DOCGXNSKUYHWMU-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)-n-[2-(isoquinolin-6-ylsulfonylamino)-2-methylpropyl]carbamate Chemical compound C1=NC=CC2=CC(S(=O)(=O)NC(C)(C)CN(CCCO)C(=O)OC(C)(C)C)=CC=C21 DOCGXNSKUYHWMU-UHFFFAOYSA-N 0.000 description 2
- PWMVAIYJTHUHEP-CQSZACIVSA-N tert-butyl n-[(2r)-2-[(7-fluoroisoquinolin-6-yl)sulfonylamino]propyl]-n-(3-hydroxypropyl)carbamate Chemical compound C1=NC=C2C=C(F)C(S(=O)(=O)N[C@@H](CN(CCCO)C(=O)OC(C)(C)C)C)=CC2=C1 PWMVAIYJTHUHEP-CQSZACIVSA-N 0.000 description 2
- BDJAHHNELXRFMU-CQSZACIVSA-N tert-butyl n-[(2r)-2-aminopropyl]-n-[3-[tert-butyl(dimethyl)silyl]oxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C[C@H](N)C)CCCO[Si](C)(C)C(C)(C)C BDJAHHNELXRFMU-CQSZACIVSA-N 0.000 description 2
- QROVPGFJNKZCQF-VIFPVBQESA-N tert-butyl n-[(2s)-2-aminopropyl]-n-(3-hydroxypropyl)carbamate Chemical compound OCCCN(C[C@@H](N)C)C(=O)OC(C)(C)C QROVPGFJNKZCQF-VIFPVBQESA-N 0.000 description 2
- BTJKWRBVNYILMX-OAHLLOKOSA-N tert-butyl n-[(3r)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-yl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 BTJKWRBVNYILMX-OAHLLOKOSA-N 0.000 description 2
- DEKWBKSTKKCXSH-SNVBAGLBSA-N tert-butyl n-[(3r)-3-aminobutyl]-n-(3-hydroxypropyl)carbamate Chemical compound C[C@@H](N)CCN(CCCO)C(=O)OC(C)(C)C DEKWBKSTKKCXSH-SNVBAGLBSA-N 0.000 description 2
- ILZPAFZXZGXYCB-OAHLLOKOSA-N tert-butyl n-[(3r)-3-hydroxybutyl]-n-[2-(isoquinolin-6-ylsulfonylamino)ethyl]carbamate Chemical compound C1=NC=CC2=CC(S(=O)(=O)NCCN(CC[C@H](O)C)C(=O)OC(C)(C)C)=CC=C21 ILZPAFZXZGXYCB-OAHLLOKOSA-N 0.000 description 2
- JABQIPXXESQRJB-MRXNPFEDSA-N tert-butyl n-[(3r)-4-hydroxy-3-methylbutyl]-n-[2-(isoquinolin-6-ylsulfonylamino)ethyl]carbamate Chemical compound C1=NC=CC2=CC(S(=O)(=O)NCCN(CC[C@H](CO)C)C(=O)OC(C)(C)C)=CC=C21 JABQIPXXESQRJB-MRXNPFEDSA-N 0.000 description 2
- XUODLUBRXWBYKH-INIZCTEOSA-N tert-butyl n-[(3s)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-yl]-n-methylcarbamate Chemical compound C1[C@@H](N(C)C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 XUODLUBRXWBYKH-INIZCTEOSA-N 0.000 description 2
- ILZPAFZXZGXYCB-HNNXBMFYSA-N tert-butyl n-[(3s)-3-hydroxybutyl]-n-[2-(isoquinolin-6-ylsulfonylamino)ethyl]carbamate Chemical compound C1=NC=CC2=CC(S(=O)(=O)NCCN(CC[C@@H](O)C)C(=O)OC(C)(C)C)=CC=C21 ILZPAFZXZGXYCB-HNNXBMFYSA-N 0.000 description 2
- QZYQGIZHPWGEMT-SNVBAGLBSA-N tert-butyl n-[(4r)-4-aminopentyl]-n-(2-hydroxyethyl)carbamate Chemical compound C[C@@H](N)CCCN(CCO)C(=O)OC(C)(C)C QZYQGIZHPWGEMT-SNVBAGLBSA-N 0.000 description 2
- CXWZKKXTFGFAHD-IBGZPJMESA-N tert-butyl n-butyl-n-[(3s)-1-isoquinolin-6-ylsulfonylpyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](N(CCCC)C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 CXWZKKXTFGFAHD-IBGZPJMESA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- OGIXGCQETYIUBZ-RXMQYKEDSA-N 2,2,2-trifluoro-n-[(2r)-5-hydroxypentan-2-yl]acetamide Chemical compound OCCC[C@@H](C)NC(=O)C(F)(F)F OGIXGCQETYIUBZ-RXMQYKEDSA-N 0.000 description 1
- UPJDZPYSTBCMFS-LLVKDONJSA-N 2,2,2-trifluoro-n-[(2r)-5-phenylmethoxypent-3-en-2-yl]acetamide Chemical compound FC(F)(F)C(=O)N[C@H](C)C=CCOCC1=CC=CC=C1 UPJDZPYSTBCMFS-LLVKDONJSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- SMWDFEZZVXVKRB-WHRKIXHSSA-N 2-deuterioquinoline Chemical compound C1=CC=CC2=NC([2H])=CC=C21 SMWDFEZZVXVKRB-WHRKIXHSSA-N 0.000 description 1
- NFNOAHXEQXMCGT-UHFFFAOYSA-N 2-phenylmethoxyacetaldehyde Chemical compound O=CCOCC1=CC=CC=C1 NFNOAHXEQXMCGT-UHFFFAOYSA-N 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- GZQGUONNDJSPTL-UHFFFAOYSA-N 5-bromo-6-(1,4-diazepan-1-ylsulfonyl)isoquinoline;dihydrochloride Chemical compound Cl.Cl.C1=CC2=CN=CC=C2C(Br)=C1S(=O)(=O)N1CCCNCC1 GZQGUONNDJSPTL-UHFFFAOYSA-N 0.000 description 1
- JDEBLBVBKMBILY-UHFFFAOYSA-N 5-bromoisoquinolin-6-amine Chemical compound C1=NC=CC2=C(Br)C(N)=CC=C21 JDEBLBVBKMBILY-UHFFFAOYSA-N 0.000 description 1
- TWZDDDXVQLBNOO-UHFFFAOYSA-N 5-bromoisoquinoline-6-sulfonyl chloride Chemical compound C1=NC=CC2=C(Br)C(S(=O)(=O)Cl)=CC=C21 TWZDDDXVQLBNOO-UHFFFAOYSA-N 0.000 description 1
- MDRROPSXMIALRC-UHFFFAOYSA-N 5-nitroisoquinoline-6-sulfonyl chloride Chemical compound N1=CC=C2C([N+](=O)[O-])=C(S(Cl)(=O)=O)C=CC2=C1 MDRROPSXMIALRC-UHFFFAOYSA-N 0.000 description 1
- WKCQDNJYUOLBPN-UHFFFAOYSA-N 6-(1,4-diazepan-1-ylsulfonyl)-2h-isoquinolin-1-one;dihydrochloride Chemical compound Cl.Cl.C=1C=C2C(=O)NC=CC2=CC=1S(=O)(=O)N1CCCNCC1 WKCQDNJYUOLBPN-UHFFFAOYSA-N 0.000 description 1
- FQRZEKXKIORLLZ-UTLKBRERSA-N 6-[[(2s)-2-methyl-1,4-diazonan-1-yl]sulfonyl]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CNCCCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 FQRZEKXKIORLLZ-UTLKBRERSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- COTVYJVDXKFNRB-UHFFFAOYSA-N 6-bromo-5-nitroisoquinoline Chemical compound N1=CC=C2C([N+](=O)[O-])=C(Br)C=CC2=C1 COTVYJVDXKFNRB-UHFFFAOYSA-N 0.000 description 1
- SEHPXAKLMRODLS-UHFFFAOYSA-N 6-bromo-7-fluoroisoquinoline Chemical compound N1=CC=C2C=C(Br)C(F)=CC2=C1 SEHPXAKLMRODLS-UHFFFAOYSA-N 0.000 description 1
- ULCYLVITTXFZCK-UHFFFAOYSA-N 6-bromo-8-fluoroisoquinoline Chemical compound C1=NC=C2C(F)=CC(Br)=CC2=C1 ULCYLVITTXFZCK-UHFFFAOYSA-N 0.000 description 1
- JWZVIMNMJGFSHD-UHFFFAOYSA-N 7-fluoroisoquinoline-6-sulfonyl chloride Chemical compound N1=CC=C2C=C(S(Cl)(=O)=O)C(F)=CC2=C1 JWZVIMNMJGFSHD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SGOWQGNSFOQQRH-UHFFFAOYSA-N 8-fluoroisoquinoline-6-sulfonyl chloride Chemical compound C1=NC=C2C(F)=CC(S(Cl)(=O)=O)=CC2=C1 SGOWQGNSFOQQRH-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 229940121819 ATPase inhibitor Drugs 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- XHNLUDHIBMNNLD-UHFFFAOYSA-N CC(C)(CNCCC1)N1Sc1ccc(cncc2)c2c1 Chemical compound CC(C)(CNCCC1)N1Sc1ccc(cncc2)c2c1 XHNLUDHIBMNNLD-UHFFFAOYSA-N 0.000 description 1
- XHRFOQBJUWPBGO-ZDUSSCGKSA-N CN[C@@H](CC1)CN1Sc1ccc(cncc2)c2c1 Chemical compound CN[C@@H](CC1)CN1Sc1ccc(cncc2)c2c1 XHRFOQBJUWPBGO-ZDUSSCGKSA-N 0.000 description 1
- GOJDSFXQOOKSGT-INIZCTEOSA-N C[C@@H](CN(CCC1)C(CNC(OC(C)(C)C)=O)=O)N1Sc1cc2ccncc2cc1 Chemical compound C[C@@H](CN(CCC1)C(CNC(OC(C)(C)C)=O)=O)N1Sc1cc2ccncc2cc1 GOJDSFXQOOKSGT-INIZCTEOSA-N 0.000 description 1
- KZVODEWRCNVNFS-AWEZNQCLSA-N C[C@@H](CN(CCC1)C(OC(C)(C)C)=O)N1Sc1ccc(cncc2)c2c1Br Chemical compound C[C@@H](CN(CCC1)C(OC(C)(C)C)=O)N1Sc1ccc(cncc2)c2c1Br KZVODEWRCNVNFS-AWEZNQCLSA-N 0.000 description 1
- DURCYMHPHSGVED-CYBMUJFWSA-N C[C@H](CC1)CNCCN1Sc1ccc(cncc2)c2c1 Chemical compound C[C@H](CC1)CNCCN1Sc1ccc(cncc2)c2c1 DURCYMHPHSGVED-CYBMUJFWSA-N 0.000 description 1
- XJBFUQXHLSQWIF-HXUWFJFHSA-N C[C@H](CN(CCCC1)C(OC(C)(C)C)=O)N1Sc1cc2ccnc(SCCNC(OC(C)(C)C)=O)c2cc1 Chemical compound C[C@H](CN(CCCC1)C(OC(C)(C)C)=O)N1Sc1cc2ccnc(SCCNC(OC(C)(C)C)=O)c2cc1 XJBFUQXHLSQWIF-HXUWFJFHSA-N 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010057615 Endocrine hypertension Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010015769 Extradural haematoma Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- PPTQWZFRPZGJEM-LLVKDONJSA-N benzyl n-[(2r)-5-hydroxypentan-2-yl]carbamate Chemical compound OCCC[C@@H](C)NC(=O)OCC1=CC=CC=C1 PPTQWZFRPZGJEM-LLVKDONJSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 229910000175 cerite Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DXTVYXOAQBXYAU-UHFFFAOYSA-N chloro ethyl carbonate Chemical compound CCOC(=O)OCl DXTVYXOAQBXYAU-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 208000014337 facial nerve disease Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002004 n-butylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004706 n-propylthio group Chemical group C(CC)S* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IGPJYNUPSNKQTA-XVKPBYJWSA-N tert-butyl (1s,4s)-2,5-diazabicyclo[2.2.1]heptane-4-carboxylate Chemical compound C1N[C@]2(C(=O)OC(C)(C)C)CN[C@@]1([H])C2 IGPJYNUPSNKQTA-XVKPBYJWSA-N 0.000 description 1
- NFHUTPPRIJOCGO-KXBFYZLASA-N tert-butyl (1s,4s)-2-isoquinolin-6-ylsulfonyl-2,5-diazabicyclo[2.2.1]heptane-4-carboxylate Chemical compound C1=NC=CC2=CC(S(=O)(=O)N3C[C@]4(NC[C@@]3(C4)[H])C(=O)OC(C)(C)C)=CC=C21 NFHUTPPRIJOCGO-KXBFYZLASA-N 0.000 description 1
- KVOFVWHEZCAJIJ-MRXNPFEDSA-N tert-butyl (3r)-3-methyl-4-(2-oxidoisoquinolin-2-ium-6-yl)sulfonyl-1,4-diazocane-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=[N+]([O-])C=C2)C2=C1 KVOFVWHEZCAJIJ-MRXNPFEDSA-N 0.000 description 1
- LJGZAWBDANVJSA-WBTMPAOCSA-N tert-butyl (3r,6z)-3-methyl-4-(2-nitrophenyl)sulfonyl-2,3,5,8-tetrahydro-1,4-diazocine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)C\C=C/CN1S(=O)(=O)C1=CC=CC=C1[N+]([O-])=O LJGZAWBDANVJSA-WBTMPAOCSA-N 0.000 description 1
- TYHKMMLSPJKQJC-OGZRUICASA-N tert-butyl (3r,6z)-4-isoquinolin-6-ylsulfonyl-3-methyl-2,3,5,8-tetrahydro-1,4-diazocine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)C\C=C/CN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 TYHKMMLSPJKQJC-OGZRUICASA-N 0.000 description 1
- LRYWPBKETMNBNS-OAHLLOKOSA-N tert-butyl (5r)-5-methyl-4-(2-oxidoisoquinolin-2-ium-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C[C@@H]1CCN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=[N+]([O-])C=C2)C2=C1 LRYWPBKETMNBNS-OAHLLOKOSA-N 0.000 description 1
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 description 1
- KVOFVWHEZCAJIJ-UHFFFAOYSA-N tert-butyl 3-methyl-4-(2-oxidoisoquinolin-2-ium-6-yl)sulfonyl-1,4-diazocane-1-carboxylate Chemical compound CC1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=[N+]([O-])C=C2)C2=C1 KVOFVWHEZCAJIJ-UHFFFAOYSA-N 0.000 description 1
- YKPSXXIDYXXTNZ-UHFFFAOYSA-N tert-butyl 4-(5-bromoisoquinolin-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1Br YKPSXXIDYXXTNZ-UHFFFAOYSA-N 0.000 description 1
- LWRDPGHBTXAGJR-UHFFFAOYSA-N tert-butyl 4-isoquinolin-6-ylsulfonyl-3-methyl-1,4-diazocane-1-carboxylate Chemical compound CC1CN(C(=O)OC(C)(C)C)CCCCN1S(=O)(=O)C1=CC=C(C=NC=C2)C2=C1 LWRDPGHBTXAGJR-UHFFFAOYSA-N 0.000 description 1
- LRYWPBKETMNBNS-UHFFFAOYSA-N tert-butyl 5-methyl-4-(2-oxidoisoquinolin-2-ium-6-yl)sulfonyl-1,4-diazepane-1-carboxylate Chemical compound CC1CCN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C=[N+]([O-])C=C2)C2=C1 LRYWPBKETMNBNS-UHFFFAOYSA-N 0.000 description 1
- BFUUARGPSQNENZ-FQEVSTJZSA-N tert-butyl N-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-N-[(2S)-2-(isoquinolin-6-ylsulfonylamino)propyl]carbamate Chemical compound C(C)(C)(C)OC(=O)N(C[C@H](C)NS(=O)(=O)C=1C=C2C=CN=CC2=CC=1)CCCO[Si](C)(C)C(C)(C)C BFUUARGPSQNENZ-FQEVSTJZSA-N 0.000 description 1
- IGJPIWZRYVGCGR-UHFFFAOYSA-N tert-butyl n-(1-aminopropan-2-yl)-n-[3-[tert-butyl(dimethyl)silyl]oxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(CN)C)CCCO[Si](C)(C)C(C)(C)C IGJPIWZRYVGCGR-UHFFFAOYSA-N 0.000 description 1
- MGQDTCWLSSUSKR-CQSZACIVSA-N tert-butyl n-(2-aminoethyl)-n-[(3r)-3-[tert-butyl(dimethyl)silyl]oxybutyl]carbamate Chemical compound CC(C)(C)[Si](C)(C)O[C@H](C)CCN(CCN)C(=O)OC(C)(C)C MGQDTCWLSSUSKR-CQSZACIVSA-N 0.000 description 1
- NAUIOEVSBWBNDU-SNVBAGLBSA-N tert-butyl n-(2-aminoethyl)-n-[(3r)-4-hydroxy-3-methylbutyl]carbamate Chemical compound OC[C@H](C)CCN(CCN)C(=O)OC(C)(C)C NAUIOEVSBWBNDU-SNVBAGLBSA-N 0.000 description 1
- MGQDTCWLSSUSKR-AWEZNQCLSA-N tert-butyl n-(2-aminoethyl)-n-[(3s)-3-[tert-butyl(dimethyl)silyl]oxybutyl]carbamate Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](C)CCN(CCN)C(=O)OC(C)(C)C MGQDTCWLSSUSKR-AWEZNQCLSA-N 0.000 description 1
- HRLVCQYPEFMWFS-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)-n-[4-[tert-butyl(dimethyl)silyl]oxybutyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CCN)CCCCO[Si](C)(C)C(C)(C)C HRLVCQYPEFMWFS-UHFFFAOYSA-N 0.000 description 1
- WTYYLCVFDOUTJH-RRKGBCIJSA-N tert-butyl n-(2-aminopropyl)-n-[(4r)-4-hydroxypentyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CC(N)C)CCC[C@@H](C)O WTYYLCVFDOUTJH-RRKGBCIJSA-N 0.000 description 1
- WTYYLCVFDOUTJH-DTIOYNMSSA-N tert-butyl n-(2-aminopropyl)-n-[(4s)-4-hydroxypentyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CC(N)C)CCC[C@H](C)O WTYYLCVFDOUTJH-DTIOYNMSSA-N 0.000 description 1
- GSJJCZSHYJNRPN-UHFFFAOYSA-N tert-butyl n-(2-sulfanylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCS GSJJCZSHYJNRPN-UHFFFAOYSA-N 0.000 description 1
- ARZMGTXAIFZCAW-UHFFFAOYSA-N tert-butyl n-(3-aminobutyl)-n-[2-[tert-butyl(dimethyl)silyl]oxyethyl]carbamate Chemical compound CC(N)CCN(C(=O)OC(C)(C)C)CCO[Si](C)(C)C(C)(C)C ARZMGTXAIFZCAW-UHFFFAOYSA-N 0.000 description 1
- JYQUUDVYFCXSSF-HNNXBMFYSA-N tert-butyl n-(3-hydroxypropyl)-n-[(2s)-2-(isoquinolin-6-ylsulfonylamino)propyl]carbamate Chemical compound C1=NC=CC2=CC(S(=O)(=O)N[C@H](CN(CCCO)C(=O)OC(C)(C)C)C)=CC=C21 JYQUUDVYFCXSSF-HNNXBMFYSA-N 0.000 description 1
- SVMNPDBDXXPRBN-GOSISDBHSA-N tert-butyl n-[(1r)-1-aminopropyl]-n-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N([C@@H](N)CC)CCN(C(=O)OC(C)(C)C)CCO[Si](C)(C)C(C)(C)C SVMNPDBDXXPRBN-GOSISDBHSA-N 0.000 description 1
- IFGUUXVCLJXWPK-MRXNPFEDSA-N tert-butyl n-[(2r)-2-[(2-nitrophenyl)sulfonyl-prop-2-enylamino]propyl]-n-prop-2-enylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC=C)C[C@@H](C)N(CC=C)S(=O)(=O)C1=CC=CC=C1[N+]([O-])=O IFGUUXVCLJXWPK-MRXNPFEDSA-N 0.000 description 1
- LLVNBTSHSAZZQU-CYBMUJFWSA-N tert-butyl n-[(2r)-2-[(2-nitrophenyl)sulfonylamino]propyl]-n-prop-2-enylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC=C)C[C@@H](C)NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O LLVNBTSHSAZZQU-CYBMUJFWSA-N 0.000 description 1
- ALVGCKICZWCYLI-SNVBAGLBSA-N tert-butyl n-[(2r)-2-aminobutyl]-n-(3-hydroxypropyl)carbamate Chemical compound CC[C@@H](N)CN(CCCO)C(=O)OC(C)(C)C ALVGCKICZWCYLI-SNVBAGLBSA-N 0.000 description 1
- QKGOBLHHNKTJNI-LLVKDONJSA-N tert-butyl n-[(2r)-2-aminobutyl]-n-(4-hydroxybutyl)carbamate Chemical compound CC[C@@H](N)CN(C(=O)OC(C)(C)C)CCCCO QKGOBLHHNKTJNI-LLVKDONJSA-N 0.000 description 1
- AHIVEVSADSAIOZ-SNVBAGLBSA-N tert-butyl n-[(2r)-2-aminopropyl]-n-[2-(2-hydroxyethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C[C@H](N)C)CCOCCO AHIVEVSADSAIOZ-SNVBAGLBSA-N 0.000 description 1
- APZJFWXETWWXBN-OAHLLOKOSA-N tert-butyl n-[(2r)-2-aminopropyl]-n-[4-[tert-butyl(dimethyl)silyl]oxybutyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C[C@H](N)C)CCCCO[Si](C)(C)C(C)(C)C APZJFWXETWWXBN-OAHLLOKOSA-N 0.000 description 1
- OFUPVUILLQKXKO-SNVBAGLBSA-N tert-butyl n-[(2r)-4-amino-2-methylbutyl]-n-(2-hydroxyethyl)carbamate Chemical compound NCC[C@@H](C)CN(CCO)C(=O)OC(C)(C)C OFUPVUILLQKXKO-SNVBAGLBSA-N 0.000 description 1
- JQJCQQIQBMVTFA-SECBINFHSA-N tert-butyl n-[(2s)-2-amino-3-fluoropropyl]-n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCCO)C[C@H](N)CF JQJCQQIQBMVTFA-SECBINFHSA-N 0.000 description 1
- NINSNRBPFAICJA-SNVBAGLBSA-N tert-butyl n-[(2s)-2-amino-3-fluoropropyl]-n-(4-hydroxybutyl)carbamate Chemical compound CC(C)(C)OC(=O)N(C[C@H](N)CF)CCCCO NINSNRBPFAICJA-SNVBAGLBSA-N 0.000 description 1
- GZXBEYWRKIPQEC-HNNXBMFYSA-N tert-butyl n-[(2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexyl]-n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)CN(CCCO)C(=O)OC(C)(C)C GZXBEYWRKIPQEC-HNNXBMFYSA-N 0.000 description 1
- BDJAHHNELXRFMU-AWEZNQCLSA-N tert-butyl n-[(2s)-2-aminopropyl]-n-[3-[tert-butyl(dimethyl)silyl]oxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C[C@@H](N)C)CCCO[Si](C)(C)C(C)(C)C BDJAHHNELXRFMU-AWEZNQCLSA-N 0.000 description 1
- APZJFWXETWWXBN-HNNXBMFYSA-N tert-butyl n-[(2s)-2-aminopropyl]-n-[4-[tert-butyl(dimethyl)silyl]oxybutyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C[C@@H](N)C)CCCCO[Si](C)(C)C(C)(C)C APZJFWXETWWXBN-HNNXBMFYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 1
- DEKWBKSTKKCXSH-JTQLQIEISA-N tert-butyl n-[(3s)-3-aminobutyl]-n-(3-hydroxypropyl)carbamate Chemical compound C[C@H](N)CCN(CCCO)C(=O)OC(C)(C)C DEKWBKSTKKCXSH-JTQLQIEISA-N 0.000 description 1
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000020049 trigeminal nerve disease Diseases 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GXIFGGMYCIQMJN-GMUIIQOCSA-N triphenyl-[(2r)-2-[(2,2,2-trifluoroacetyl)amino]propyl]phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C[C@@H](C)NC(=O)C(F)(F)F)C1=CC=CC=C1 GXIFGGMYCIQMJN-GMUIIQOCSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Description
R1及びR2はそれぞれ独立して水素原子、ハロゲン原子、シアノ基、アルキル基、ハロゲノアルキル基、アルケニル基、アルコキシ基、アルキルチオ基、ヒドロキシ基、メルカプト基、ニトロ基、アリール基、アミノ基又はアミノアルキルチオ基を示し;
R3及びR4はそれぞれ独立して水素原子、アルキル基、アルケニル基、アミノ基、アルキルアミノ基、ジアルキルアミノ基、アミノアルキル基、ハロゲノアルキル基、アルカノイル基、アミノアルカノイル基、アルキルアミノアルカノイル基、アルコキシカルボニル基、ヒドロキシ基又はメルカプト基を示すか、あるいはR3とR4が一緒になってアルキレン基又はアルケニレン基を形成し、任意の位置へ2つの炭素間で架橋していてもよく;
l、m及びnは1〜4の数を示す。)
で表されるイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物を提供するものである。
また本発明は、緑内障、循環器疾患、又は神経変性若しくは神経損傷に起因する疾患若しくは障害を予防又は治療するための上記一般式(1)で表されるイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物を提供するものである。
さらに本発明は、上記一般式(1)で表されるイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物の有効量を投与することを特徴とする緑内障、循環器疾患、又は神経変性若しくは神経損傷に起因する疾患若しくは障害の予防治療方法を提供するものである。
具体例としては、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基、イソブチル基、sec−ブチル基、tert−ブチル基、n−ペンチル基、イソペンチル基、n−ヘキシル基、イソヘキシル基、シクロプロピル基を挙げることができる。なかでも炭素数1〜3のものが好ましく、特にメチル基、エチル基が好ましい。
アルキルアミノ基としては、C1-8アルキルアミノ基が好ましく、具体例としてはメチルアミノ基、エチルアミノ基、n−プロピルアミノ基、イソプロピルアミノ基、n−ブチルアミノ基、イソブチルアミノ基、sec−ブチルアミノ基、n−ペンチルアミノ基、n−ヘキシルアミノ基等が挙げられる。ジアルキルアミノ基としては、ジ−C1-8アルキルアミノ基が好ましく、具体例としてはジメチルアミノ基、ジエチルアミノ基、ジプロピルアミノ基、ジブチルアミノ基等が挙げられる。アミノアルキル基としては、アミノC1-8アルキル基が好ましく、具体例としてはアミノメチル基、アミノエチル基、アミノプロピル基、アミノブチル基等が挙げられる。
また、R3及びR4としては、それぞれ独立して水素原子、C1-8アルキル基、アミノ基、C1-8アルキルアミノ基、アミノC1-8アルキル基又はハロゲノC1-8アルキル基であるか、あるいはR3とR4とが一緒になって架橋C1-3のアルキレン基を形成するのがより好ましい。
さらにR3及びR4は水素原子、C1-6アルキル基又はハロゲノC1-6アルキル基であるのが好ましい。
6−(ピペラジン−1−イルスルホニル)イソキノリン、
(R)−6−(3−アミノピロリジン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(4−アミノピペリジン−1−イルスルホニル)イソキノリン、
5−ブロモ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゼパン−1−イルスルホニル)−8−フルオロイソキノリン、
6−{(1S,4S)−2,5−ジアザビシクロ[2.2.1]ヘプタン−2−イルスルホニル}イソキノリン、
(R,Z)−6−(2−メチル−2,3,4,5−テトラヒドロ−1,4−ジアゾシン−1(8H)−イルスルホニル)イソキノリン、
6−(モルホリン−1−イルスルホニル)イソキノリン、
(S)−6−{3−(N−メチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン、
(S)−6−{3−(N−ブチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン、
(S)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチルピペラジン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(3−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−エチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−エチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
6−(2,2−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)−7−フルオロイソキノリン、
(S)−6−(2−フルオロメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−フルオロメチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン、
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(6−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(7−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン、
(R)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(2R,7R)−6−(2,7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(2S, 7R)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(8−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)−5−ニトロイソキノリン、
(2R, 6R)−6−(2, 6−ジメチルピペラジン−1−イルスルホニル)イソキノリン、
(2S, 7S)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(5−メチル−1,4, 7−オキサジアゾナン−4−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4,7−トリアゾナン−1−イルスルホニル)イソキノリン、
6−(4−グリシル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(4−グリシル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(4−グリシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(4−サルコシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−5−メチル−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−1−(2−アミノエチルチオ)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン−1(2H)−オン、
1−アミノ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
1−ニトリル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−(4−アミノブチル)−1、4−ジアゼピン−1−イルスルホニル)イソキノリン、
6−(4−メトキシカルボニルピペリジン−1−イルスルホニル)イソキノリン、
(S)−6−(3−ヒドロキシピロリジン−1−イルスルホニル)イソキノリン、
5−フェニル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン
から成る群より選択される化合物、その塩又はその溶媒和物。
製造法1
一般式(1a)で表されるハロゲン体をR10及びR11に対応するグリニヤール試薬若しくはアルキルリチウムなどの有機金属試薬、アルカリ金属水酸化物(例、水酸化ナトリウム、水酸化カリウム)、ナトリウムアルコラート(例、ナトリウムメチラート、ナトリウムエチラート)などのアルカリ、又はシアン化カリウムで処理することにより化合物(1b)を製造する。本反応は、公知の方法に準じて行うことができる。
またパラジウム触媒存在下に行なわれる鈴木―宮浦カップリングを用いても合成できる。
化合物(1c)をXに対応するアミン、グアニジン又はアンモニアと反応させることにより化合物(1d)を製造する。本反応は、公知の方法(Acta Chemica Scand., 45,621(1991))に準じて行うことができる。
化合物(1d)は、化合物(1g)をトリフェニルホスフィンなどの有機リン試薬とアゾジカルボン酸ジエチル又はアゾジカルボン酸ジイソプロピルなどのアゾ試薬を用いて分子内脱水反応(いわゆる光延反応)を行い、続いて保護基R12を除去することによって得ることができる。
(第2工程)化合物(1h)のヒドロキシ基をそれ自体公知の方法で、ハロゲン(例、塩素、臭素)、アシルオキシ(例、トシルオキシ、メタンスルホニルオキシ、アセチルオキシ)に変換して、その後化合物(1i)を製造する。
(第3工程)化合物(1i)とアミノアルキルアルコールを適当な溶媒中、塩基の存在又は不存在下で、製造法1と同様に反応させることにより、化合物(1g)を製造する。
また、化合物(1g)は、化合物(2)と対応するアミノアルコールを反応させることにより1工程で合成することも可能である。
(第4工程)化合物(1g)の2級アミノの窒素原子を必要に応じて、公知の方法で保護した後、常法に従い化合物(1g)を化合物(1j)に変換することができる。
(第5工程)化合物(1j)を適当な溶媒中、塩基で処理し、必要により酸又はアルカリ処理して保護基を除去して化合物(1d)を製造する。塩基としては、水素化ナトリウム、炭酸水素ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウムのようなアルカリ、トリエチルアミン、トリエチレンジアミン等の有機第3級アミンを用いることができる。反応溶媒として製造法1で例示したものを用い、同様の反応条件で反応させる。
また、化合物(1d)は製造法5に従い、分子内脱水反応(いわゆる光延反応)と続くR12の脱保護により合成することもできる。
式中R13はホルミル基、ハロメチル基、ハロゲン又はアセチルオキシメチル、メシルオキシメチル若しくはトシルオキシメチル等のアシルオキシメチルを挙げることができる。R13がホルミル基の場合、還元的アミノ化により2級アミンを合成し、その後トシル基やメシル基で代表されるスルホニルハライドと反応させることにより化合物(2b)を合成できる。R13がハロメチル基、ハロゲン又はアセチルオキシメチル、メシルオキシメチル若しくはトシルオキシメチル等のアシルオキシメチルの場合、アミンによる置換反応により化合物(2b)を合成できる。化合物(2b)を強酸、及びルイス酸存在下反応させることにより、化合物(2c)を合成できる。化合物(2c)から化合物(2)の合成は、公知の方法を用いて合成できる。
本発明化合物は、公知の方法により、前記した塩を形成させることができる。例えば、本発明化合物の塩酸塩は、本発明化合物を塩化水素のアルコール溶液又はエチルエーテル溶液に溶解することにより得ることができる。
本発明化合物は、結晶多形をとる場合がある。その結晶多形も本発明に含まれる。
より詳細には、高血圧症としては、本態性高血圧症、腎性高血圧症、腎血管性高血圧、妊娠誘発性高血圧、内分泌性高血圧、心臓血管性高血圧、神経性高血圧、医原生高血圧、肺高血圧症等が例示され、動脈硬化症としては、冠動脈・腹部大動脈・腎動脈・頚動脈・眼底動脈・脳動脈等全身主要動脈に病変が生じたものが例示される。脳循環障害としては、脳血栓、脳梗塞、脳出血、一過性脳虚血発作、高血圧性脳症、脳動脈硬化症、硬膜下血腫、硬膜外血腫、クモ膜下出血、脳低酸素症、脳浮腫、脳炎、脳膿瘍、頭部外傷、精神病、代謝中毒、薬物中毒、一過性の呼吸停止、手術時の深麻酔等が例示される。心臓病は、うっ血性心不全、急性心筋梗塞、陳旧性心筋梗塞、心内膜下梗塞、右室梗塞、非定型的心筋梗塞、虚血性心筋症、異型狭心症、安定狭心症、労作性狭心症、冠レン縮性狭心症、梗塞後狭心症、不安定狭心症、不整脈、急性心臓死等を含む。
末梢循環障害には、バージャー病、閉塞性動脈硬化症、レイノー症候群等の動脈疾患及び静脈血栓症、血栓性静脈炎等の静脈疾患、血液の過粘性症候群、凍傷・凍創、冷え性による冷感及び入眠障害、褥創、ひび・あかぎれ、脱毛が含まれる。
また、末梢神経系に関する疾患として、例えば、三叉神経障害、顔面神経障害、単ニューロパチー、多発性ニューロパチー、糖尿病性ニューロパチー、外傷性神経麻痺を含むがこれらに限定されない。
また、網膜神経及び視神経に関する疾患として例えば、緑内障、加齢黄斑変性症、網膜色素変性症、糖尿病性網膜症、網膜神経炎、視神経炎、視神経断裂、外傷性視神経症を含むがこれらに限定されない。
例えば、錠剤、カプセル剤、顆粒剤、散剤等の経口剤は、乳糖、マンニトール、デンプン、結晶セルロース、軽質無水ケイ酸、炭酸カルシウム、リン酸水素カルシウム等の賦形剤、ステアリン酸、ステアリン酸マグネシウム、タルク等の滑沢剤、デンプン、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン等の結合剤、カルボキシメチルセルロース、低置換度ヒドロキシプロピルメチルセルロース、クエン酸カルシウム等の崩壊剤、ヒドロキシプロピルメチルセルロース、マクロゴール、シリコーン樹脂等のコーティング剤、パラオキシ安息香酸エチル、ベンジルアルコール等の安定化剤、甘味料、酸味料、香料等の矯味矯臭剤等を必要に応じて本発明化合物に組合わせて、調製することができる。
また、注射剤、点眼剤等の非経口剤は、例えば、グリセリン、プロピレングリコール、塩化ナトリウム、塩化カリウム、ソルビトール、マンニトール等の等張化剤、リン酸、リン酸塩、クエン酸、氷酢酸、ε−アミノカプロン酸、トロメタモール等の緩衝剤、塩酸、クエン酸、リン酸、氷酢酸、水酸化ナトリウム、水酸化カリウム、炭酸ナトリウム、炭酸水素ナトリウム等のpH調節剤、ポリソルベート80、ポリオキシエチレン硬化ヒマシ油60、マクロゴール4000、精製大豆レシチン、ポリオキシエチレン(160)ポリオキシプロピレン(30)グリコール等の可溶化又は分散剤、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース等のセルロース系高分子、ポリビニルアルコール、ポリビニルピロリドン等の増粘剤、エデト酸、エデト酸ナトリウム等の安定化剤、汎用のソルビン酸、ソルビン酸カリウム、塩化ベンザルコニウム、塩化ベンゼトニウム、パラオキシ安息香酸メチル、パラオキシ安息香酸プロピル、クロロブタノール等の保存又は防腐剤、クロロブタノール、ベンジルアルコール、リドカイン等の無痛化剤を必要に応じて本発明化合物に組合わせて、調製することができる。
また、点眼剤であれば通常0.0001%〜10%(w/v)、好ましくは0.01%〜5%(w/v)の濃度のものを1回又は数回に分けて投与することができる。静脈内投与の場合、1日あたり、0.1〜100mg/ヒトの範囲、好ましくは、1〜30mg/ヒトの範囲である。経口投与の場合、1日あたり、1〜1,000mg/ヒトの範囲、好ましくは、10〜30mg/ヒトの範囲である。場合によっては、これ以下でも足りるし、また逆にこれ以上の用量を必要とすることもある。また、1日2〜3回に分割して投与することもできる。
(参考例1)
6−アミノイソキノリン(参考化合物1)の合成
1H-NMRスペクトル (CDCl3, δ ppm): 5.54 (br s, 2H), 6.58 (s, 1H), 7.00 (d, J = 9.0 Hz, 1H ), 7.35 (d, J = 5.5 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 5.5 Hz, 1H), 8.98 (s, 1H)
6−クロロスルホニルイソキノリン(参考化合物2)の合成
6−クロロスルホニル−8−フルオロイソキノリン(参考化合物3)の合成
5−ブロモ−6−クロロスルホニルイソキノリン(参考化合物4)の合成
6−クロロスルホニル−7−フルオロイソキノリン(参考化合物5)の合成
6−クロロスルホニル−5−ニトロイソキノリン(参考化合物6)の合成
以下、参考化合物7〜34は、WO2006/115244及びUS2008/064681に準じて合成した。
(R)−4−アミノ−N−(tert−ブトキシカルボニル)−N−(2−ヒドロキシエチル)ペンチルアミン(参考化合物35)の合成
N−[(R)−4−(ベンジルオキシ)−1−メチル−ブト−2−エニル]−トリフルオロアセトアミドの合成
1H-NMRスペクトル(CDCl3, δ ppm): 1.31 (d, J = 6.0 Hz, 1.5H), 1.33 (d, J = 6.0 Hz, 1.5H), 4.14 -4.16 (m, 2H), 4.52 (s, 2H), 4.58-4.63 (m, 0.5H), 4.77-4.79 (m, 0.5H), 5.46-5.50 (m, 0.5H), 5.75 -5.80 (m, 1.5H), 6.17 (br s, 0.5H), 6.43 (br s, 0.5H), 7.30-7.41 (m, 5H)
(R)−4−(トリフルオロアセチルアミノ)−1−ペンタノールの合成
1H-NMRスペクトル(CDCl3, δ ppm):1.24 (d, J = 6.0 Hz, 3H), 1.52 (dd, J = 5.0 Hz, 1H), 1.59 -1.69 (m, 4H), 3.69-3.72 (m, 2H), 4.05-4.08 (m, 1H), 6.59 (br s, 1H)
(R)−4−(ベンジルオキシカルボニルアミノ)−1−ペンタノールの合成
1H-NMRスペクトル(CDCl3, δ ppm):1.15 (d, J = 6.5 Hz, 3 H), 1.25-1.31 (m, 1H), 1.53-1.60 (m, 4H), 3.66-3.77 (m, 3H), 4.59-4.70 (m, 1H), 5.08 (s, 2H), 7.31-7.36 (m, 5H)
(R)−4−アミノ−N−(tert−ブトキシカルボニル)−N−(2−ヒドロキシエチル)ペンチルアミン(参考化合物35)の合成
1H-NMRスペクトル(CDCl3, δ ppm):1.07 (d, J = 6.0 Hz, 3 H), 1.27-1.31 (m, 2H), 1.46 (s, 9H), 1.58 (m, 1H), 1.78-1.85 (m, 4H), 2.88-2.91 (m, 1H), 3.20-3.25 (m, 2H), 3.35-3.40 (m, 2H), 3.70-3.75 (m, 2H)
(R、Z)−4−tert−ブトキシカルボニル−2−メチル−1、2,3,4,5、8−ヘキサヒドロ−1,4−ジアゾシン(参考化合物36)の合成
(R)−N−{1−(アリルアミノ)プロパン−2−イル}−2−ニトロベンゼンスルホンアミドの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.16 (d, J = 6.7 Hz, 3H), 2.60 (ddd, J = 26.7, 12.7, 6.0 Hz, 2H), 3.08 (d, J = 6.1 Hz, 2H), 3.50-3.52 (m, 1H), 5.03-5.07 (m, 3H), 5.72-5.75 (m, 1H), 6.21 (br s,1H), 7.73-7.74 (m, 3H), 8.16-8.18 (m, 1H)
(R)−N−[1−{アリル(tert−ブトキシカルボニル)アミノ}プロパン−2−イル]−2−ニトロベンゼンスルホンアミドの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.10 (d, J = 5.9 Hz, 3H), 1.43 (s, 9H), 3.13 (dd, J = 5.0, 14.0 Hz, 1H), 3.24-3.36 (m, 1H), 3.72 (s, 2H), 3.77-3.84 (m, 1H), 5.05-5.11 (m, 2H), 5.68 (br s, 1H), 5.86 (br s, 1H), 7.73 (s, 2H), 7.84 (s, 1H), 8.13 (d, J = 6.2 Hz, 1H)
(R)−N−アリル−N−[1−{アリル(tert−ブトキシカルボニル)アミノ}プロパン−2−イル]−2−ニトロベンゼンスルホンアミドの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.18 (d, J = 6.3 Hz, 3H), 1.45 (s, 9H), 3.20-3.43 (m, 2H), 3.69-3.83 (m, 2H), 3.99 (s, 2H), 4.25 (q, J = 6.4 Hz, 1H), 5.02-5.20 (m, 4H), 5.69-5.78 (m, 2H), 7.62-7.69 (m, 3H), 8.04 (s, 1H)
(R、Z)−4−tert−ブトキシカルボニル−2−メチル−1−(2−ニトロフェニルスルホニル)−1、2,3,4,5、8−ヘキサヒドロ−1,4−ジアゾシンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.07 (d, J = 4.6 Hz, 1.5H), 1.09 (d, J = 4.6 Hz, 1.5H), 1.47 (s, 9H), 3.47-3.65 (m, 1H), 3.80 (d, J = 18.9 Hz, 1H), 4.06-4.28 (m, 5H), 5.71 (s, 2H), 7.66-7.69 (m, 3H), 8.03 (s, 1H)
(R、Z)−4−tert−ブトキシカルボニル−2−メチル−1、2,3,4,5、8−ヘキサヒドロ−1,4−ジアゾシン(参考化合物36)の合成
1H-NMRスペクトル (CDCl3, δ ppm):1.04 (d, J = 3.1 Hz, 1.5H), 1.06 (d, J = 3.1 Hz, 1.5H), 1.46 (s, 9H), 1.78 (br s,1H), 2.82 (dd, J = 9.8, 13.4 Hz, 0.5H), 2.92 (dd, J = 9.8, 14.0 Hz, 0.5H), 3.10-3.16 (m, 1H), 3.30 (dd, J = 4.9, 15.9 Hz, 1H), 3.53-3.67 (m, 2H), 3.87 (d, J = 17.4 Hz, 0.5 H), 3.89 (d, J = 17.4 Hz, 0.5H), 4.16 (dd, J = 4.6, 17.4 Hz, 0.5H), 4.35 (dd, J = 3.4, 17.4 Hz, 0.5H), 5.60-5.76 (m, 2H)
2−アミノ−1−(tert−ブトキシカルボニル−3−ヒドロキシプロピルアミノ)−2−メチルプロパン(参考化合物37)の合成
ベンジル 1−ヒドロキシ2−メチルプロパン−2−イルカルバメートの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.28 (s, 6H), 1.51 (br s,1H), 3.60 (d, J = 6.0 Hz, 2H), 5.29 (s, 2H), 6.12 (s, 1H), 7.26-7.38 (m, 5H)
ベンジル 2−メチル−1−オキソプロパン−2−イルカルバメートの合成
この反応液に、トリエチルアミン3.6mLを滴下し、10分間攪拌した後、−10度まで徐々に昇温しつつ、1時間半攪拌した。反応終了後、反応液に水を加え、ジクロロメタン(30mL×2)で抽出し、抽出液を無水硫酸ナトリウムで乾燥した。ろ過を行い、ろ液を濃縮して得られた粗生成物をシリカゲルカラムクロマトグラフィー(酢酸エチル:ヘキサン=1:2)で精製し、目的物960mgを白色固体として得た。(65%)
1H-NMRスペクトル (CDCl3, δ ppm):1.39 (s, 6H), 5.09 (s, 2H), 6.23 (br s, 1H), 7.28-7.40 (m, 5H), 9.43 (s, 1H)
2−(ベンジルオキシカルボニルアミノ)−1−(tert−ブトキシカルボニル−3−ヒドロキシプロピルアミノ)−2メチルプロパンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.33 (s, 6H), 1.46 (s, 9H), 1.60-1.79 (m, 3H), 3.29-3.63 (br m, 6H), 5.04 (s, 2H), 6.31 (br s, 1H), 7.27-7.37 (m, 5H)
2−アミノ−1−(tert−ブトキシカルボニル−3−ヒドロキシプロピルアミノ)−2−メチルプロパン(参考化合物37)の合成
1H-NMRスペクトル (CDCl3, δ ppm):1.15 (s, 6H), 1.47 (s, 9H), 1.75 (br s, 2H), 1.95 (br s, 3H), 3.12 (br s, 2H), 3.53 (br s, 4H)
6−(ピペラジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物1)の合成
ステップ1
6−(4−tert−ブトキシカルボニルピペラジン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):2.42 (s,9H), 3.11 (d, J= 4.9 Hz, 4H), 3.40 (s, 4H), 7.56 (d, J= 9.2 Hz, 1H), 7.58 (d, J = 5.5 Hz, 1H), 7.83 (s, 1H), 7.93 (d, J= 8.5 Hz, 1H), 8.55 (d, J = 5.5 Hz, 1H), 9.24 (s, 1H)
6−(ピペラジン−1−イルスルホニル)イソキノリン二塩酸塩の合成
1H-NMRスペクトル (DMSO-d6, δppm):2.98 (d, J= 4.3 Hz, 4H), 3.39 (s, 4H), 4.33 (br s, 1H), 7.99 (d, J = 7.9 Hz, 1H), 8.19 (s, 1H), 8.47 (d, J = 8.5 Hz, 1H), 8.50 (br s, 2H), 8.59 (s, 1H), 8.72 (dd, J = 5.5, 11.0 Hz, 1H), 9.58 (s, 1H)
融点:242度
(R)−6−(3−アミノピロリジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物2)の合成
(R)−6−(3−tert−ブトキシカルボニルアミノピロリジン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.37 (s, 9H), 1.77-1.80 (m, 1H), 2.05-2.09 (m, 1H), 3.29 (s, 2H), 3.45-3.52 (m, 2H), 4.09-4.14 (m, 1H), 4.48 (s, 1H), 7.81 (d, J = 5.5 Hz, 1H), 7.96 (dd, J = 1.8, 8.5 Hz, 1H), 8.16 (d, J = 9.2 Hz, 1H), 8.38 (s, 1H), 8.71 (d, J = 5.5 Hz, 1H), 9.39 (s, 1H)
(R)−6−(3−アミノピロリジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物2)の合成
1H-NMRスペクトル (DMSO-d6, δppm):1.83-1.85 (m, 1H), 2.03-2.06 (m, 1H), 3.25-3.28 (m, 1H), 3.31 (dd, J = 10.7, 4.0 Hz, 1H), 3.44 (dd, J = 7.0, 10.7 Hz, 1H), 3.50 (dd, J = 7.9, 16.5 Hz, 1H), 3.70 (s, 1H), 4.36 (br s, 2H), 8.11 (d, J = 5.5 Hz, 1H), 8.38 (d, J = 5.5 Hz, 1H), 8.54 (d, J = 8.5 Hz, 1H), 8.59 (br s, 1H), 8.63 (br s, 1H), 8.69 (s, 1H), 8.75 (d, J = 6.1 Hz, 1H), 9.73 (s, 1H)
融点:281度
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物3)の合成
6−(4−tert−ブトキシカルボニル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.41 (s, 9H), 1.96-1.97 (m, 2H), 3.31-3.32 (m, 2H), 3.35-3.42 (m, 2H), 3.47-3.58 (m, 4H), 7.78 (d, J= 5.5 Hz, 1H), 7.89 (d, J = 8.5 HZ, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.34 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.36 (s, 1H)
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物3)の合成
1H-NMRスペクトル (D2O, δ ppm): 1.99-2.03 (m, 2H), 3.27 (t, J= 5.5 Hz, 2H), 3.30 (t, J = 5.2 Hz, 2H), 3.41 (t, J = 6.1 Hz, 2H), 3.60 (t, J = 5.5 Hz, 2H), 8.14-8.15 (m, 1H), 8.41-8.46 (m, 1H), 8.53 (d, J = 6.7 Hz, 2H), 8.66 (s, 1H), 9.65 (dd, J = 5.2, 8.2 Hz, 1H)
融点:204度
6−(4−アミノピペリジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物4)の合成
6−{4−(tert−ブトキシカルボニルアミノ)ピペリジン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.40 (s, 9H), 1.48-1.53 (m, 2H), 2.00 (d, J = 12.2 Hz, 2H), 2.56 (t, J = 11.6 Hz, 2H), 3.40 (s, 1H), 3.80 (d, J = 10.4 Hz, 2H), 4.39 (s, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.88 (d, J= 8.5 Hz, 1H), 8.15 (d, J = 9.2 Hz, 1H), 8.32 (s, 1H), 8.71 (d, J= 5.5 Hz, 1H), 9.40 (s, 1H)
6−(4−アミノピペリジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物4)の合成
1H-NMRスペクトル (DMSO-d6, δppm):1.54 (dd, J= 3.8, 11.7 Hz, 2H), 1.94 (d, J= 10.4 Hz, 2H), 2.49-2.52 (m, 2H), 3.01-3.03 (m, 1H), 3.74 (d, J = 12.8 Hz, 2H), 5.13 (bs s, 2H), 8.01 (dd, J = 1.2, 8.5 Hz, 1H), 8.02 (br s, 2H), 8.28 (d, J = 5.5 Hz, 1H), 8.49 (d, J = 9.2 Hz, 1H), 8.59 (s, 1H), 8.73 (d, J= 6.1 Hz, 1H), 9.66 (s, 1H)
融点:290度
5−ブロモ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物5)の合成
1H-NMRスペクトル (DMSO-d6, δppm):2.05 (t, J= 4.9 Hz, 2H), 3.19-3.25 (m, 4H), 3.50 (t, J = 6.1 Hz, 2H), 3.76 (t, J= 4.6 Hz, 2H), 4.96 (br s, 1H), 8.12 (br s, 2H), 8.20 (d, J = 8.5 Hz, 1H), 8.27 (d, J = 6.1 Hz, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.81 (d, J = 6.1 Hz, 1H), 9.61 (s, 1H)
融点:215度
6−(1,4−ジアゼパン−1−イルスルホニル)−8−フルオロイソキノリン二塩酸塩(化合物6)の合成
1H-NMRスペクトル (DMSO-d6, δppm): 1.96-2.00 (m, 2H), 3.15 (s, 2H), 3.20 (s, 2H), 3.41 (t, J = 5.8 Hz, 2H), 3.62 (t, J = 4.9 Hz, 2H), 4.52 (br s, 1H), 7.88 (dd, J = 1.2, 9.8 Hz, 1H), 8.22 (d, J = 5.5 Hz, 1H), 8.27 (br s, 2H), 8.45 (s, 1H), 8.82 (d, J = 5.5 Hz, 1H), 9.62 (s, 1H)
融点:208度
6−{(1S,4S)−2,5−ジアザビシクロ[2.2.1]ヘプタン−2−イルスルホニル}イソキノリン二塩酸塩(化合物7)の合成
6−{(1S,4S)−4−tert−ブトキシカルボニル−2,5−ジアザビシクロ[2.2.1]ヘプタン−2−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.39-1.43 (m, 1H), 1.58 (s, 9H), 1.74 (m, 1H), 3.26-3.33 (m, 2H), 3.43-3.52 (m, 2H), 4.36 (s, 0.5 H), 4.47 (s, 0.5 H), 4.56 (s, 1H), 7.80 (s, 1H), 7.98 (d, J = 7.9 Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.71 (br s, 1H), 9.40 (br s, 1H)
6−{(1S,4S)−2,5−ジアザビシクロ[2.2.1]ヘプタン−2−イルスルホニル}イソキノリン二塩酸塩(化合物7)の合成
1H-NMRスペクトル (D2O, δ ppm):1.38 (d, J = 11.6 Hz, 1H), 1.75 (d, J = 11.6 Hz, 1H), 3.28 (dd, J = 2.4, 11.6 Hz, 2H), 3.43 (td, J = 2.2, 10.8 Hz, 2H), 3.61 (d, J = 11.0 Hz, 1H), 4.34 (s, 1H), 8.21-8.23 (m, 1H), 8.44 (t, J = 5.5 Hz, 1H), 8.57 (d, J = 7.3 Hz, 2H), 8.72 (s, 1H), 9.67 (s, 1H)
融点:192度
(R,Z)−6−(2−メチル−2,3,4,5−テトラヒドロ−1,4−ジアゾシン−1(8H)−イルスルホニル)イソキノリン二塩酸塩(化合物8)の合成
(R,Z)−6−(4−tert−ブトキシカルボニル−2−メチル−2,3,4,5−テトラヒドロ−1,4−ジアゾシン−1(8H)−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.98 (d, J = 5.2 Hz, 1.5H), 1.00 (d, J = 5.2 Hz, 1.5Hz), 1.47 (s, 9H), 3.59 (m, 3H), 3.71 (d, J = 17.1 Hz, 1H), 4.07-4.14 (m, 1H), 4.22-4.29 (m, 2H), 5.61-5.70 (m, 1H), 5.76-5.81 (m, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.90 (dd, J = 1.8, 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.37 (s, 1H), 8.68 (d, J = 6.1 Hz, 1H), 9.36 (s, 1H)
(R,Z)−6−(2−メチル−2,3,4,5−テトラヒドロ−1,4−ジアゾシン−1(8H)−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.96 (d, J = 6.1 Hz, 3H), 2.59 (br s, 1H), 2.73 (dd, J = 2.4, 14.6 Hz, 1H), 3.04 (dd, J = 6.1, 14.6 Hz, 1H), 3.52 (dd, J = 4.3, 16.5 Hz, 1H), 3.78 (dd, J = 5.2, 16.2 Hz, 1H), 4.08-4.14 (m, 2H), 4.27 (dd, J = 5.5, 16.5 Hz, 1H), 5.53-5.57 (m, 1H), 5.83-5.88 (m, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.95 (dd, J = 1.2, 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.67 (d, J = 6.1 Hz, 1H), 9.35 (s, 1H)
(R,Z)−6−(2−メチル−2,3,4,5−テトラヒドロ−1,4−ジアゾシン−1(8H)−イルスルホニル)イソキノリン二塩酸塩(化合物8)の合成
1H-NMRスペクトル (D2O, δ ppm):0.71 (d, J = 6.7 Hz, 3H), 3.11 (dd, J = 3.1, 14.6 Hz, 1H), 3.21 (t, J = 13.4 Hz, 1H), 3.57 (dd, J = 8.9, 13.7 Hz, 1H), 3.84 (d, J = 20.1 Hz, 1H), 4.53 (m, 3H), 5.61 (d, J = 11.0 Hz, 1H), 6.07 (d, J = 11.0 Hz, 1H), 8.20 (t, J = 6.7 Hz, 1H), 8.38-8.44 (m, 1H), 8.54 (dd, J = 6.7, 14.6 Hz, 2H), 8.71 (s, 1H), 9.63 (d, J = 7.3 Hz, 1H)
[α]25 D−59.0(c=0.031,H2O)
6−(モルホリン−1−イルスルホニル)イソキノリン塩酸塩(化合物9)の合成
6−(モルホリン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):3.10 (t, J = 4.6 Hz, 4H), 3.76 (t, J = 4.6 Hz, 4H), 7.81 (d, J = 5.5 Hz, 1H), 7.89 (dd, J = 1.2, 8.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.33 (s, 1H), 8.71 (d, J = 5.5 Hz, 1H), 9.41 (s, 1H)
6−(モルホリン−1−イルスルホニル)イソキノリン塩酸塩(化合物9)の合成
1H-NMRスペクトル (D2O, δ ppm):3.08 (t, J = 4.6 Hz, 4H), 3.66 (t, J = 4.6 Hz, 4H), 8.14 (d, J = 8.5 Hz, 1H), 8.47 (d, J = 6.7 Hz, 1H), 8.57 (t, J = 7.0 Hz, 2H), 8.64 (s, 1H), 9.69 (s, 1H)
融点:202度
(S)−6−{3−(N−メチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン二塩酸塩(化合物10)の合成
(S)−6−{3−(tert−ブトキシカルボニルアミノ)ピロリジン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.37 (s, 9H), 1.79 (br s, 1H), 2.06-2.09 (m, 1H), 3.26-3.33 (m, 2H), 3.44-3.52 (m, 2H), 4.10 (s, 1H), 4.49 (s, 1H), 7.82 (d, J = 4.3 Hz, 1H), 7.96 (dd, J = 1.2, 8.5 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.38 (s, 1H), 8.72 (s, 1H), 9.41 (s, 1H)
(S)−6−{3−(N−tert−ブトキシカルボニル−N−メチルアミノ)ピロリジン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.13 (s, 9H), 1.89-1.97 (m, 1H), 1.98-2.04 (m, 1H), 2.71 (s, 3H), 3.15 (s, 1H), 3.23 (t, J = 7.9 Hz, 1H), 3.40 (t, J = 8.5 Hz, 1H), 3.60 (s, 1H), 4.62 (br s, 1H), 7.81 (d, J = 6.1 Hz, 1H), 7.96 (dd, J = 1.2, 8.5 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.38 (s, 1H), 8.70 (d, J = 5.5 Hz, 1H), 9.39 (s, 1H)
(S)−6−{3−(N−メチルアミノ)ピロリジン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.57 (br s, 1H), 1.62-1.69 (m, 1H), 1.98-2.05 (m, 1H), 2.30 (s, 3H), 3.13 (dd, J = 4.6, 10.1 Hz, 1H), 3.16-3.20 (m, 1H), 3.35-3.40 (m, 1H), 3.42-3.46 (m, 1H), 3.48-3.52 (m, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.98 (dd, J = 1.2, 8.5 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.68 (d, J = 6.1 Hz, 1H), 9.37 (s, 1H)
(S)−6−{3−(N−メチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン二塩酸塩(化合物10)の合成
1H-NMRスペクトル (D2O, δ ppm):1.97-2.03 (m, 1H), 2.13-2.21 (m, 1H), 2.60 (s, 3H), 3.18-3.24 (m, 1H), 3.44 (dd, J = 6.4, 11.3 Hz, 1H), 3.54-3.59 (m, 2H), 3.68-3.72 (m, 1H), 8.19 (dd, J = 2.1, 8.9 Hz, 1H), 8.45 (dd, J = 3.4, 6.4 Hz, 1H), 8.56 (d, J = 6.7 Hz, 2H), 8.69 (s, 1H), 9.67 (s, 1H)
融点:189度
[α]25 D+30.3(c=0.038,H2O)
(S)−6−{3−(N−ブチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン二塩酸塩(化合物11)の合成
(S)−6−{3−(N−tert−ブトキシカルボニル−N−ブチルアミノ)ピロリジン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.87 (t, J = 7.3 Hz, 3H), 1.18-1.23 (m, 2H), 1.34 (s, 9H), 1.39-1.44 (m, 2H), 1.94-2.05 (m, 2H), 2.96-3.07 (m, 2H), 3.18-3.22 (m, 2H), 3.50 (t, J = 9.2 Hz, 1H), 3.55 (s, 1H), 4.27 (br s, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.97 (dd, J = 1.8, 8.5 Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.38 (s, 1H), 8.70 (d, J = 6.1 Hz, 1H), 9.39 (s, 1H)
(S)−6−{3−(N−ブチルアミノ)ピロリジン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.81 (t, J = 7.0 Hz, 3H), 1.14-1.29 (m, 5H), 1.60-1.66 (m, 1H), 1.99-2.06 (m, 1H), 2.38-2.47 (m, 2H), 3.08 (dd, J = 4.9, 10.4 Hz, 1H), 3.23-3.27 (m, 1H), 3.36-3.45 (m, 2H), 3.52 (dd, J = 6.1, 10.4 Hz, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.98 (dd, J = 1.8, 8.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.69 (d, J = 5.5 Hz, 1H), 9.38 (s, 1H)
(S)−6−{3−(N−ブチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン二塩酸塩(化合物11)の合成
1H-NMRスペクトル (D2O, δ ppm):0.76 (t, J = 7.3 Hz, 3H), 1.20-1.25 (m, 2H), 1.46-1.52 (m, 2H), 1.94-1.99 (m, 1H), 2.15-2.21 (m, 1H), 2.89-2.92 (m, 2H), 3.18-3.23 (m, 1H), 3.46-3.58 (m, 3H), 3.71-3.74 (m, 1H), 8.20 (d, J = 7.9 Hz, 1H), 8.54-8.59 (m, 3H), 8.70 (s, 1H), 9.70 (s, 1H)
融点:207度
[α]25 D+30.0(c=0.053,H2O)
(S)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物12)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.12 (s, 1.5H), 1.13(s, 1.5H), 1.48 (m, 9H), 1.62 (s, 2H), 2.90 (m, 1H), 3.03-3.08 (m, 4H), 3.30-3.32 (m, 1H), 3.50 (s, 2H), 3.62 (s, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.94-7.96 (m, 1H), 8.11-8.12 (m, 1H), 8.41 (s, 1H), 8.69 (d, J = 3.7 Hz, 1H), 9.37 (s, 1H)
1H-NMRスペクトル (CDCl3, δ ppm):0.95 (d, J = 6.7 Hz, 1.5H), 0.99 (d, J = 6.7 Hz, 1.5H), 1.46 (s, 9H), 1.73-1.78 (m, 2H), 3.09-3.14 (m, 2H), 3.52-3.76 (m, 2H), 3.87 (m, 1H), 3.91 (m, 1H), 4.43 (dd, J= 6.7, 12.8 Hz, 1H), 7.79 (d, J= 5.5 Hz, 1H), 7.92 (t, J = 8.2 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.68 (s, 1H), 9.37 (s, 1H)
(S)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩の合成
(1)(S)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.99 (d, J = 6.7 Hz, 3H), 1.66-1.79 (m, 3H), 2.49 (dd, J= 8.5, 14.6 Hz, 1H), 2.65-2.69 (m, 1H), 3.01 (td, J = 4.1, 9.0 Hz, 1H), 3.16-3.20 (m, 2H), 3.85 (d, J = 15.9 Hz, 1H), 4.18 (dd, J = 6.4, 13.7 Hz, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.45 (s, 1H), 8.67 (d, J = 5.5 Hz, 1H), 9.35 (s, 1H)
1H-NMRスペクトル (D2O, δ ppm):0.81 (d, J = 6.7 Hz, 3H), 1.99 (m, 2H), 3.00 (m, 2H), 3.30 (m, 1H), 3.41 (m, 1H), 3.55 (dd, J = 5.8, 14.3 Hz, 1H), 3.84 (m, 1H), 4.46 (m, 1H), 8.23 (d, J = 8.5 Hz, 1H), 8.48 (s, 1H), 8.54 (m, 2H), 8.72 (s, 1H), 9.67 (s, 1H)
融点:232度
[α]25 D+88.3(c=0.043,H2O)
(S)−6−(2−メチルピペラジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物13)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチルピペラジン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.95 (m, 3H), 1.40 (s, 9H), 2.00 (d, J = 12.2 Hz, 2H), 2.56 (t, J = 11.6 Hz, 2H), 3.80 (d, J = 10.4 Hz, 2H), 4.39 (s, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.88 (d, J= 8.5 Hz, 1H), 8.15 (d, J = 9.2 Hz, 1H), 8.43 (s, 1H), 8.71 (d, J= 5.5 Hz, 1H), 9.40 (s, 1H)
(S)−6−(2−メチルピペラジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物13)の合成
1H-NMRスペクトル (D2O, δ ppm):1.07 (d, J = 7.3 Hz, 3H), 2.97 (td, J = 4.3, 12.8 Hz, 1H), 3.11 (dd, J = 4.3, 13.4 Hz, 1H), 3.20 (d, J = 13.4 Hz, 1H), 3.32 (d, J = 12.8 Hz, 1H), 3.42-3.48 (m, 1H), 3.96 (d, 15.3 Hz, 1H), 4.44 (t, J = 5.8 Hz, 1H), 8.17-8.20 (m, 1H), 8.41-8.46 (m, 1H), 8.56 (d, J = 7.3 Hz, 2H), 8.72 (s, 1H), 9.65-9.66 (m, 1H)
融点:229度
[α]25 D+39.7(c=0.045,H2O)
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物14)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.84 (d, J = 6.7 Hz, 1.5H), 0.88 (d, J = 6.7 Hz, 1.5H), 1.47 (s, 9H), 1.70-1.81 (m, 2H), 1.91 (s, 2H), 2.99-3.09 (m, 1H), 3.32-3.39 (m, 1H), 3.43-3.53 (m, 3H), 3.62 (td, J = 4.9, 9.8 Hz, 1H), 4.23-4.28 (m, 1H), 7.79 (d, J = 4.3 Hz, 1H), 7.92 (dd, J = 1.2, 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.38 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.36 (s, 1H)
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物14)の合成
1H-NMRスペクトル (D2O, δ ppm):0.63 (d, J = 6.1 Hz, 3H), 1.76-2.01 (m, 4H), 3.19 (m, 4H), 3.41 (dd, J = 7.6, 13.7 Hz, 1H), 3.65 (d, J = 15.3 Hz, 1H), 4.36-4.41 (m, 1H), 8.26 (d, J = 9.2 Hz, 1H), 8.48 (d, J = 6.7 Hz, 1H), 8.56 (t, J = 8.2 Hz, 2H), 8.75 (s, 1H), 9.35 (s, 1H)
融点:197度
[α]24 D−60.8(c=0.046,H2O)
(S)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物15)の合成
(S)−5−ブロモ−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.86 (d, J = 6.4 Hz, 1.5H), 0.90 (d, J = 6.4 Hz, 1.5H), 1.49 (d, J = 2.4 Hz, 9H), 1.83-1.94 (m, 2H), 3.17-3.29 (m, 4H), 3.64-3.71 (m, 2H), 4.29 (t, J = 6.1 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 8.21 (t, J = 4.6 Hz, 1H), 8.32 (dd, J = 8.5, 18.9 Hz, 1H), 8.75 (d, J = 4.3 Hz, 1H), 9.36 (s, 1H)
(S)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物15)の合成
1H-NMRスペクトル (D2O, δ ppm):0.79 (d, J = 6.7 Hz, 3H), 2.03 (m, 2H), 3.11 (m, 2H), 3.41 (td, J = 4.3, 9.2 Hz, 1H), 3.50 (m, 2H), 4.04 (dt, J = 5.3, 10.4 Hz, 1H), 4.35 (m, 1H), 8.30 (d, J = 9.2 Hz, 1H), 8.36 (d, J = 9.2 Hz, 1H), 8.59 (d, J = 6.7 Hz, 1H), 8.62 (d, J = 6.7 Hz, 1H), 9.57 (s, 1H)
融点:251度
6−(3−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物16)の合成
6−(4−tert−ブトキシカルボニル−3−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.07 (d, J = 6.4 Hz, 1.5H), 1.12 (d, J = 6.4 Hz, 1.5H), 1.43 (s, 4.5H), 1.47 (s, 4.5H), 1.95 (br s, 2H), 2.78-2.88 (m, 2H), 3.77-3.94 (m, 3H), 4.32-4.47 (m, 1H), 4.94-4.95 (m, 1H), 7.79 (d, J = 6.1 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 8.11 (s, 1H), 8.37 (s, 1H), 8.68 (s, 1H), 9.36 (d, J = 4.9 Hz, 1H)
6−(3−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物16)の合成
1H-NMRスペクトル (D2O, δ ppm):1.24 (d, J = 6.7 Hz, 3H), 1.94-1.99 (m, 1H), 2.04-2.10 (m, 1H), 3.16-3.20 (m, 1H), 3.22-3.36 (m, 3H), 3.46-3.51 (m, 1H), 3.56-3.62 (m, 1H), 3.68 (m, 1H), 8.12 (dd, J = 1.5, 8.6 Hz, 1H), 8.38 (d, J = 6.7 Hz, 1H), 8.52 (dd, J = 7.9, 10.4 Hz, 2H), 8.64 (s, 1H), 9.62 (s, 1H)
融点:吸湿性により測定不可
6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物17)の合成
6−(4−tert−ブトキシカルボニル−7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.97-1.11 (m, 3H), 1.40 (s, 9H), 1.54-1.73 (m, 2H), 2.56 (t, J = 9.4 Hz, 2H), 3.30 (br s, 2H), 3.78-3.85 (m, 2H), 4.39 (s, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 8.14-8.16 (m, 2H), 8.71 (d, J = 5.5 Hz, 1H), 9.38 (s, 1H)
6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物17)の合成
1H-NMRスペクトル (D2O, δ ppm):0.75 (d, J = 6.7 Hz, 3H), 1.63 (m, 2H), 2.26-2.33 (m, 1H), 3.02-3.08 (m, 2H), 3.35-3.42 (m, 2H), 3.95-3.97 (m, 1H), 4.17-4.21 (m, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.39 (d, J= 6.7 Hz, 1H), 8.52 (dd, J = 11.3, 7.6 Hz, 2H), 8.69 (s, 1H), 9.61 (s, 1H)
融点:84度(吸湿性のため、測定途中で潮解)
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物18)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.95 (d, J = 6.7 Hz, 1.5H), 0.99 (d, J = 6.7 Hz, 1.5H), 1.41 (s, 4.5H), 1.43 (s, 4.5H), 1.67-1.91 (m, 2H), 3.06-3.20 (m, 3H), 3.60-3.76 (m, 2H), 3.88 (d, J = 15.6 Hz, 0.5H), 3.89 (d, J = 15.6 Hz, 0.5H), 4.43 (td, J = 6.3, 12.8 Hz, 1H), 7.77 (d, J = 6.1 Hz, 1H), 7.91 (t, J= 8.9 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.67 (d, J= 5.5 Hz, 1H), 9.35 (s, 1H)
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物18)の合成
1H-NMRスペクトル (D2O, δ ppm):0.83 (d, J = 6.7 Hz, 3H), 1.97-2.09 (m, 2H), 3.00-3.03 (m, 2H), 3.31 (m, 1H), 3.43 (dt, J = 4.5, 9.2 Hz, 1H), 3.57 (dd, J = 6.1, 14.6 Hz, 1H), 3.86 (dt, J = 5.3, 9.9 Hz, 1H), 4.48 (dt, J = 5.0, 12.2 Hz, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.49 (d, J = 6.1 Hz, 1H), 8.56 (t, J = 7.3 Hz, 2H), 8.74 (s, 1H), 9.69 (s, 1H)
融点:224度
[α]24 D−84.3(c=0.043,H2O)
(R)−6−(2−エチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物19)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−エチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.62-0.75 (m, 3H), 1.39-1.46 (m, 11H), 1.70-1.76 (m, 2H), 3.00-3.04 (m, 1H), 3.39-3.61 (m, 4H), 3.81-4.12 (m, 2H), 7.77 (d, J = 5.5 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 8.09 (d, J = 9.0 Hz, 1H), 8.39 (s, 1H), 8.67 (d, J = 5.5 Hz, 1H), 9.35 (s, 1H)
(R)−6−(2−エチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物19)の合成
1H-NMRスペクトル (DMSO-d6, δppm):0.57 (t, J = 7.2 H, 3H), 1.48-1.58 (m, 2H), 1.88-1.90 (m, 3H), 3.05-3.08 (m, 2H), 3.24-3.37 (m, 3H), 3.79-3.84 (m, 1H), 4.22-4.26 (m, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.31 (br s, 1H), 8.46(d, J = 8.5 Hz, 1H), 8.70 (s, 3H), 9.13 (br s, 1H), 9.49 (br s, 1H)
融点:199〜200度
[α]26 D−35.0(c=0.049,H2O)
(R)−6−(2−エチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物20)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−エチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.47-0.50 (m, 3H), 1.18-1.27 (m, 2H), 1.46 (s, 9H), 1.71-1.85 (m, 4H), 2.96-3.24 (m, 2H), 3.46-3.94 (m, 5H), 7.78 (d, J = 6.0 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.36 (s, 1H), 8.67 (d, J = 6.0 Hz, 1H), 9.35 (s, 1H)
(R)−6−(2−エチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物20)の合成
1H-NMRスペクトル (DMSO-d6, δppm):0.55 (t, J = 7.2 H, 3H), 1.13-1.21 (m, 1H), 1.36-142 (m, 1H), 1.60-1.84 (m, 4H), 3.06-3.17 (m, 4H),3.26-3.48 (m, 2H), 3.63-3.69 (m, 1H), 4.12-4.16 (m, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.57-8.59 (m, 4H), 8.81 (s, 1H), 9.18 (bs, 1H), 9.47 (br s, 1H)
融点:99〜100度
[α]25 D−21.3(c=0.043,H2O)
6−(1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物21)の合成
6−(4−tert−ブトキシカルボニル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.46 (s, 9H), 1.57 (s, 4H), 1.61-1.67 (m, 2H), 3.24 (s, 2H), 3.28 (t, J= 7.0 Hz, 2H), 3.69 (t, J = 6.1 Hz, 2H), 7.80 (d, J = 6.1 Hz, 1H), 7.91 (dd, J = 1.8, 8.5 Hz, 1H), 8.14 (d, J = 7.9 Hz, 1H), 8.35 (s, 1H), 8.69 (d, J = 5.5 Hz, 1H), 9.38 (s, 1H)
6−(1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物21)の合成
1H-NMRスペクトル (D2O, δ ppm):1.92-1.95 (m, 2H), 2.04-2.08 (m, 2H), 3.05-3.10 (m, 2H), 3.38-3.40 (m, 4H), 3.70-3.74 (m, 2H), 8.11 (d, J= 8.5 Hz, 1H), 8.33-8.36 (m, 1H), 8.51 (d, J = 8.5 Hz, 1H), 8.54 (d, J= 6.7 Hz, 1H), 8.63 (s, 1H), 9.60 (s, 1H)
融点:吸湿性により測定不可
6−(2,2−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物22)の合成
6−{2−(tert−ブトキシカルボニル−3−ヒドロキシプロピルアミノ)−1,1−ジメチルエチルアミノスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.24 (s, 6H), 1.54 (s, 9H), 1.69-1.77 (m, 3H), 3.16-3.67 (br m, 6H), 5.92 (br s, 1H), 7.75 (d, J = 5.5 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 8.05 (br s, 1H), 8.40 (s, 1H), 8.65 (d, J = 5.3 Hz, 1H), 9.34 (s, 1H)
6−(2,2−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.51 (s, 6H), 1.54-1.65 (m, 2H),1.94 (br s, 1H), 2.80-2.85 (m, 4H), 3.60-3.66 (m, 2H), 7.77 (d, J = 6.1 Hz, 1H), 8.03 (dd, J = 1.8, 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.46 (s, 1H), 8.65 (d, J = 6.1 Hz, 1H), 9.34 (s, 1H)
6−(2,2−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物22)の合成
1H-NMRスペクトル (D2O, δ ppm):1.40 (s, 6H), 1.87-1.94 (m, 2H), 3.16 (t, J = 6.1 Hz, 2H), 3.30 (s, 2H), 3.75-3.80 (m, 2H), 8.21 (dd, J = 1.8, 8.6 Hz, 1H), 8.41 (d, J = 6.56 Hz, 1H), 8.5-8.59 (m, 2H), 8.73 (s, 1H), 9.64 (s, 1H)
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物23)の合成
(R)−5−ブロモ−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.89 (d, J = 6.4 Hz, 1.5H), 0.91 (d, J = 6.4 Hz, 1.5H), 1.48 (d, J = 8.5 Hz, 9H), 1.83-2.00 (m, 4H), 3.17-3.19 (m, 1H), 3.39-3.52 (m, 4H), 3.93-3.96 (m, 1H), 4.06-4.08 (m, 1H), 8.03 (t, J = 9.5 Hz, 1H), 8.22 (s, 1H), 8.30 (d, J = 8.5 Hz, 1H), 8.75 (d, J = 5.5 Hz, 1H), 9.36 (s, 1H)
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物23)の合成
1H-NMRスペクトル (D2O, δ ppm):0.70 (d, J = 6.8 Hz, 3H), 1.79-1.93 (m, 1H), 1.97-2.06 (m, 1H), 3.25 (d, J = 8.0 Hz, 2H), 3.27-3.30 (m, 1H), 3.36-3.42 (m, 1H), 3.49-3.54 (m,1H), 3.36-3.42 (m, 1H), 3.49-3.54 (m, 1H), 4.04 (dt, J = 4.5, 15.6 Hz, 1H), 4.17-4.25 (m, 1H), 8.40 (dd, J = 8.8, 13.7 Hz, 2H), 8.66 (dd, J = 6.9, 12.5 Hz, 2H), 9.63 (s, 1H)
融点:192度
(S)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物24)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.84 (d, J = 6.7 Hz, 1.5H), 0.88 (d, J = 6.7 Hz, 1.5H), 1.47 (s, 9H), 1.70-1.81 (m, 2H), 1.91 (s, 2H), 2.99-3.09 (m, 1H), 3.32-3.39 (m, 1H), 3.43-3.56 (m, 3H), 3.62 (td, J = 4.9, 9.8 Hz, 1H), 4.14-4.28 (m, 1H), 7.79 (d, J = 4.3 Hz, 1H), 7.92 (dd, J = 1.2, 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.38 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.37 (s, 1H)
(S)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物24)の合成
1H-NMRスペクトル (D2O, δ ppm):0.68 (d, J = 7.1 Hz, 3H), 1.77-2.07 (m, 4H), 3.16-3.47 (m, 4H), 3.45 (ddd, J = 1.8, 7.9, 13.4 Hz, 1H), 3.69 (dt, J = 4.7, 15.2 Hz, 1H), 4.39-4.44 (m, 1H), 8.22 (d, J = 8.9 Hz, 1H), 8.36 (t, J = 5.1 Hz, 1H), 8.52 (d, J = 8.3 Hz, 1H), 8.58 (d, J = 6.3 Hz, 1H), 8.72 (s, 1H), 9.61 (s, 1H)
融点:182度
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)−7−フルオロイソキノリン二塩酸塩(化合物25)の合成
(R)−6−{2−(tert−ブトキシカルボニル−3−ヒドロキシプロピルアミノ)−1−メチルエチルアミノスルホニル}−7−フルオロイソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.13 (d, J = 5.7 Hz, 3H), 1.38 (s, 9H), 1.58 (s, 1H), 1.69 (s, 1H), 1.93 (br s, 1H), 3.03 (dd, J = 4.8, 14.5 Hz, 1H), 3.17-3.34 (m, 2H), 3.47 (s, 2H), 3.59-3.75 (m, 2H), 5.54 (br s, 1H), 7.74-7.77 (m, 2H), 8.47 (d, J = 7.0 Hz, 1H), 8.66 (s, 1H), 9.31 (s, 1H)
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)−7−フルオロイソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.96 (d, J = 6.7 Hz, 3H), 1.54-1.66 (m, 3H), 2.52-2.59 (m, 1H), 2.72-2.79 (m, 1H), 3.05-3.12 (m, 1H), 3.17-3.29 (m, 2H), 3.93-4.00 (m, 1H), 4.19-4.28 (m, 1H), 7.71 (d, J = 10 Hz, 1H), 7.76 (d, J = 5.5 Hz, 1H), 8.56 (d, J = 6.7 Hz, 1H), 8.65 (d, J = 5.5 Hz, 1H), 9.29 (s, 1H)
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)−7−フルオロイソキノリン二塩酸塩(化合物25)の合成
1H-NMRスペクトル (D2O, δ ppm):0.88 (d, J = 6.8 Hz, 3H), 2.05-2.09 (m, 2H), 3.09-3.17 (m, 2H), 3.45-3.50 (m, 2H), 3.56-3.60 (dd, J = 5.9, 14.7 Hz, 1H), 3.97-4.00 (dt, J = 4.3, 15.7 Hz, 1H), 4.42-4.50 (m, 1H), 8.26 (d, J = 9.8 Hz, 1H), 8.44 (d, J = 6.1 Hz, 1H), 8.59 (s, 1H), 8.80 (d, J = 6.7 Hz, 1H), 9.63 (s, 1H)
[α]24 D−91.3(c=0.048,H2O)
(S)−6−(2−フルオロメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物26)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−フルオロメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm):1.47 (s, 9H), 1.65-1.78 (m, 2H), 3.03-3.26 (m, 2H), 3.42-3.47 (m, 1H), 3.68-3.81 (m, 3H), 3.91-4.00 (m, 1H), 4.35-4.53 (m, 2H), 7.78 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.67 (br s, 1H), 9.35 (br s, 1H)
(S)−6−(2−フルオロメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物26)の合成
1H-NMRスペクトル(D2O, δ ppm): 2.05-2.12 (m, 2H), 3.06-3.11 (m, 1H), 3.28-3.33 (m, 1H), 3.44-3.52 (m, 2H), 3.75-3.79 (m, 1H), 3.99-4.01 (m, 1H), 4.30-4.34 (m, 1H), 4.40-4.44 (m, 1H), 4.73-4.76 (m, 1H), 8.25 (d, J = 8.7 Hz, 1H), 8.44 (br s, 1H), 8.55 (d, J = 8.7 Hz, 1H), 8.64 (br s, 1H), 8.74 (s, 1H), 9.71 (br s, 1H)
(R)−6−(2−フルオロメチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物27)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−フルオロメチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm):1.44 (s, 9H), 1.71-1.89 (m, 4H), 3.12-3.16 (m, 1H), 3.28-3.32 (m, 1H), 3.44-3.48 (m, 2H), 3.57-3.61 (m, 2H), 3.71-3.75 (m, 1H), 4.31-4.47 (m, 2H), 7.93 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 2H), 8.37 (s, 1H), 8.67 (br s, 1H), 9.35 (br s, 1H)
(R)−6−(2−フルオロメチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物27)の合成
1H-NMRスペクトル(D2O, δ ppm): 1.59-1.60 (m, 1H), 1.78-1.80 (m, 2H), 1.87-1.97 (m, 1H), 3.10-3.17 (m, 2H), 3.30-3.33 (m, 2H), 3.69-3.72 (m, 2H), 4.26-4.30 (m, 1H), 4.35-4.39 (m, 1H), 4.55-4.65 (m, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.33(br s, 1H), 8.46 (d, J = 8.5 Hz, 1H), 8.56 (br s, 1H), 8.73 (s, 1H), 9.09 (br s, 1H)
[α]24 D−52.9(c=0.034,H2O)
(S)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン二塩酸塩(化合物28)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.92 (d, J = 7.1 Hz, 1.5H), 1.14 (d, J = 7.1 Hz, 1.5H), 1.59 (s, 9H), 1.68-1.77 (m, 2H), 1.80-1.88 (m, 3H), 1.89-1.98 (m, 1H), 3.14-3.21 (m, 1H), 3.33 (dd, J = 8.0, 15.3 Hz, 1H), 3.39-3.46 (m, 3H), 3.70 (s, 1H), 4.07-4.13 (m, 1H), 7.77 (d, J = 6.1 Hz, 1H), 7.93 (dd, J = 1.8, 8.2 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.35 (s, 1H), 8.67 (d, J = 6.1 Hz, 1H), 9.35 (s, 1H)
(S)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物28)の合成
1H-NMRスペクトル (D2O, δ ppm):0.66 (d, J = 6.4 Hz, 3H), 1.73-1.84 (m, 4H), 1.87-2.02 (m, 2H), 3.16-3.24 (m, 4H), 3.43-3.49 (m, 2H), 4.44 (s, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.45 (dd, J = 6.1, 11.1 Hz, 1H), 8.58 (d, J = 5.3 Hz, 1H), 8.61 (d, J = 5.9 Hz, 1H), 8.77 (s, 1H), 8.86 (s, 1H)
融点:吸湿性により測定不可
[α]24 D+36.9(c=0.021,H2O)
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物29)の合成
(R)−5−ブロモ−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.84 (d, J = 7.2 Hz, 1.5H), 0.94 (d, J = 6.5 Hz, 1.5H), 1.48 (s, 9H), 1.78-1.96 (m, 2H), 3.16-3.32 (m, 3H), 3.62-3.74 (m, 2H), 3.98-4.13 (m, 2H), 8.03 (d, J = 7.6 Hz, 1H), 8.21 (t, J = 4.7 Hz, 1H), 8.32 (d, J = 8.5 Hz, 1H), 8.74 (dd, J = 2.1, 6.3 Hz, 1H), 9.36 (s, 1H)
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物29)の合成
1H-NMRスペクトル (D2O, δ ppm):0.84 (d, J = 6.7 Hz, 3H), 2.04-2.09 (m, 2H), 3.11-3.18 (m, 2H), 3.45 (dt, J = 4.5, 13.7 Hz, 1H), 3.52-3.58 (m, 2H), 4.08 (dt, J = 4.7, 15.4 Hz, 1H), 4.34-4.39 (m, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 8.3 Hz, 1H), 8.64 (s, 2H), 9.60 (s, 1H)
融点:吸湿性のため測定不可
(R)−6−(6−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物30)の合成
(R)−6−[3−{(tert−ブトキシカルボニル−2−ヒドロキシエチルアミノ)メチル}ブチルアミノスルホニル]イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.83 (d, J = 6.5 Hz, 3H), 1.43 (s, 9H), 1.52-1.62 (m, 2H), 1.80-1.90 (br m, 2H), 2.80-3.53 (br m, 6H), 3.68-3.82 (br m, 2H), 6.14 (s, 1H), 7.79 (d, J = 5.5 Hz, 1H), 7.99 (d, J = 9.1 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.42 (s, 1H), 8.69 (d, J = 5.6 Hz, 1H), 9.34 (s, 1H)
(R)−6−(6−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.98 (d, J = 6.7 Hz, 3H), 1.61-1.70 (m, 2H), 1.95-2.09 (m, 2H), 2.77 (dd, J = 9.2, 13.5 Hz, 1H), 3.06-3.30 (m, 5H), 3.33-3.41 (m, 1H), 3.55-3.60 (m, 1H), 7.78 (d, J = 5.49 Hz, 1H), 7.90 (dd, J = 1,83, 8.55 Hz, 1H), 8.12 (d, J = 8.54 Hz, 1H), 8.33 (s, 1H), 8.68 (d, J = 6.1 Hz, 1H), 9.37 (s, 1H)
(R)−6−(6−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物30)の合成
1H-NMRスペクトル (D2O, δ ppm):0.99 (d, J = 6.6 Hz, 3H), 1.64-1.71 (m, 1H), 1.87-1.90 (m, 1H), 2.15 (br s, 1H), 3.10-3.15 (m, 2H), 3.30-3.44 (m, 4H), 3.50-3.57 (m, 1H), 3.61-3.66 (m, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.44 (d, J = 6.6 Hz, 1H), 8.56-8.59 (m, 2H), 8.68 (s, 1H), 9.67 (s, 1H)
[α]25 D+9.7(c=0.059,H2O)
(R)−6−(7−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物31)の合成
1H-NMRスペクトル (CDCl3, δ ppm):0.85 (d, J = 6.6 Hz, 3H), 1.45 (s, 9H), 1.49-1.66 (br m, 4H), 3.04-3.50 (m, 8H), 5.76 (br s, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 8.12(d, J = 8.4 Hz, 1H), 8.40 (s, 1H), 8.68 (d, J = 5.7 Hz, 1H), 9.37 (s, 1H)
(R)−6−(7−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.95 (d, J = 6.6 Hz, 3H), 1.37-1.52 (br m,2H), 1.89-1.99 (br m, 2H), 2.91-3.20 (m, 6H), 3.24-3.32 (m, 1H), 3.39-3.46 (m, 1H), 7.79 (d, J = 5.5 Hz, 1H) 7.91 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 8.6 Hz, 1H), 8.34 (s, 1H), 8.69 (d, J = 6.0 Hz, 1H), 9.37 (s, 1H)
(R)−6−(7−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物31)の合成
1H-NMRスペクトル (D2O, δ ppm):0.85 (d, J = 6.7 Hz, 3H), 1.61-1.70 (m, 1H), 1.92-2.06 (m, 2H), 2.92-2.99 (m, 1H), 3.19-3.26 (m, 1H), 3.26-3.34 (m, 2H), 3.35-3.43 (m, 2H), 3.44-3.51 (m, 1H), 3.60-3.68 (m, 1H), 8.17 (dd, J = 1.8, 9.2 Hz, 1H), 8.42 (d, J = 6.1 Hz, 1H), 8.53-8.58 (m, 2H), 8.67 (s, 1H), 9.66 (s, 1H)
[α]24 D+9.6(c=0.050,H2O)
(S)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物32)の合成
(R)−6−{2−(3−ヒドロキシブチル−tert−ブトキシカルボニルアミノ)エチルアミノスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.15 (d, J = 7.3 Hz, 3H), 1.43 (s, 9H), 1.46-1.50 (m, 2H), 1.91 (br s, 1H), 3.02 (br s, 1H), 3.17 (s, 3H), 3.44 (br s, 1H), 3.69 (br s, 1H), 3.80 (s, 1H), 6.22 (br s, 1H), 7.79 (d, J = 6.6 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H), 8.13 (d, J = 7.3 Hz, 1H), 8.41 (s, 1H), 8.69 (d, J = 5.8 Hz, 1H), 9.36 (s, 1H)
(S)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物32)の合成
1H-NMRスペクトル (D2O, δ ppm):0.80 (d, J = 6.1 Hz, 3H), 1.63-1.72 (m, 1H), 2.34 (dt, J = 7.1, 17.6 Hz, 1H), 3.04-3.15 (m, 2H), 3.39-3.47 (m, 3H), 4.00 (d, J = 16.9 Hz, 1H), 4.23 (dt, J = 6.3, 9.7 Hz, 1H), 8.22 (dd, J = 1.8, 8.5 Hz, 1H), 8.42 (d, J = 7.4 Hz, 1H), 8.54 (d, J = 9.0 Hz, 1H), 8.57 (d, J = 6.6 Hz, 1H), 8.73 (s, 1H), 9.64 (s, 1H)
融点:吸湿性のため測定不可
(R)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン二塩酸塩(化合物33)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.91 (d, J = 7.1 Hz, 1.5H), 1.13 (d, J = 7.1 Hz, 1.5H), 1.47 (s, 9H), 1.70-1.80 (m, 2H), 1.85 (br s, 3H), 1.93-1.98 (m, 1H), 3.20-3.27 (m, 1H), 3.37 (dd, J = 6.8, 15.3 Hz, 1H), 3.40-3.49 (m, 3H), 3.67 (s, 1H), 4.11 (br s, 1H), 7.78 (d, J = 6.1 Hz, 1H), 7.97 (dd, J = 1.8, 8.2 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.69 (d, J = 6.1 Hz, 1H), 9.36 (s, 1H)
(R)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン二塩酸塩(化合物33)の合成
1H-NMRスペクトル (D2O, δ ppm):0.63 (d, J = 4.7 Hz, 3H), 1.69-1.89 (m, 6H), 2.95-3.20 (m, 4H), 3.42-3.48 (m, 2H), 4.42 (br s, 1H), 8.24 (dd, J = 2.1, 8.9 Hz, 1H), 8.40 (dd, J = 3.0, 6.2 Hz, 1H), 8.57 (d, J = 8.3 Hz, 1H), 8.58 (d, J = 6.8 Hz, 1H), 8.73 (s, 1H), 9.63 (s, 1H)
融点:吸湿性により測定不可
(R)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物34)の合成
(S)−6−{2−(3−ヒドロキシブチル−tert−ブトキシカルボニルアミノ)エチルアミノスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.27 (d, J = 7.3 Hz, 3H), 1.43 (s, 11H), 1.91 (br s, 1H), 3.02 (s, 1H), 3.17 (s, 1H), 3.50-3.63 (m, 4H), 3.80 (s, 1H), 6.20 (br s, 1H), 7.78 (d, J = 6.1 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 7.9 Hz, 1H), 8.41 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.36 (s, 1H)
(R)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.02 (d, J = 6.7 Hz, 3H), 1.70 (br s, 2H), 2.15-2.21 (m, 1H), 2.61 (dd, J = 9.2, 13.4 Hz, 1H), 2.91-2.95 (m, 3H), 3.12-3.17 (m, 1H), 3.87 (d, J = 15.3 Hz, 1H), 4.16-4.20 (m, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.35 (s, 1H)
(R)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物34)の合成
1H-NMRスペクトル (D2O, δ ppm):0.78 (d, J = 6.1 Hz, 3H), 1.67 (dt, J =8.4, 19.1 Hz, 1H), 2.33 (dt, J = 7.5, 16.5 Hz, 1H), 3.03-3.13 (m, 2H), 3.41-3.44 (m, 3H), 3.98 (d, J = 17.1 Hz, 1H), 4.21-4.24 (m, 1H), 8.23 (dd, J = 1.8, 9.2 Hz, 1H), 8.46 (d, J = 6.1 Hz, 1H), 8.56 (d, J = 3.7 Hz, 1H), 8.57 (s, 1H), 8.74 (s, 1H), 9.68 (s, 1H)
融点:吸湿性のため測定不可
(2R,7R)−6−(2,7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物35)の合成
(2R,7R)−6−(4−tert−ブトキシカルボニル−2,7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.09-1.21 (m, 3H), 1.31-1.43 (m, 3H), 1.49 (s, 9H), 1.88-2.16 (br m, 2H), 3.36-3.79 (br m, 6H), 7.77 (d, J = 5.5 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 8.10 (d, J = 8.8 Hz, 1H), 8.38 (s, 1H), 8.67 (d, J = 5.5 Hz, 1H), 9.34 (s, 1H)
6−{(2R,7R)−2,7−ジメチル−1,4−ジアゼパン−1−イルスルホニル}イソキノリン二塩酸塩(化合物35)の合成
1H-NMRスペクトル (D2O, δ ppm):0.93 (d, J = 6.7 Hz, 3H), 1.36 (d, J = 7.3 Hz, 3H), 1.71-1.82 (m, 1H), 2.28-2.37 (m, 1H), 3.18-3.32 (m, 2H), 3.39-3.49 (m, 2H), 3.83-3.92 (m, 1H), 4.21-4.32 (m, 1H), 8.15 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 6.4 Hz, 1H), 8.45 (d, J = 9.4 Hz, 1H), 8.53 (d, J = 6.1 Hz, 1H), 8.64 (s, 1H), 9.53 (s, 1H)
[α]25 D−64.3(c=0.033,H2O)
(2S, 7R)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物36)の合成
(2S, 7R)−6−(4−tert−ブトキシカルボニル−2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm): 1.20-1.35 (m, 6H), 1.44 (s, 9H), 1.80-1.83 (m, 1H), 2.04-2.05 (m, 1H), 3.15-3.20 (m, 1H), 3.42-3.46 (m, 3H), 4.35-4.39 (m, 1H), 4.47-4.50 (m, 1H), 7.82 (s, 1H), 7.93 (d, J = 9.0 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.41 (s, 1H), 8.69 (s, 1H), 9.36 (s, 1H)
(2S, 7R)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物36)の合成
1H-NMRスペクトル(D2O, δ ppm): 1.10 (d, J = 6.5 Hz, 3H), 1.26 (d, J = 6.5 Hz, 3H), 1.89-1.96 (m, 1H), 2.25-2.28 (m, 1H), 2.99-3.04 (m, 1H), 3.11-3.14 (m, 1H), 3.27-3.31 (m, 1H), 3.34-3.38 (m, 1H), 4.40-4.42 (m, 1H), 4.50-4.52 (m, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.52 (br s, 1H), 8.56 (d, J = 8.5 Hz, 1H), 8.73-8.76 (m, 2H), 9.63 (s, 1H)
[α]25 D−22.5(c=0.030,H2O)
(R)−6−(8−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物37)の合成
(R)−6−(4−tert−ブトキシカルボニル−8−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm):0.65 (d, J = 6.0 Hz, 3 H), 1.45 (s, 9H), 1.48-1.66 (m, 4H), 3.07-3.13 (m, 1H), 3.18-3.23 (m, 1H), 3.30-3.37 (m, 1H), 3.50-3.52 (m, 1H), 3.72-3.76 (m, 1H), 4.08-4.14 (m, 2H), 7.78 (d, J = 5.5 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.38 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.36 (br s, 1H)
(R)−6−(8−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩の合成
1H-NMRスペクトル(D2O, δ ppm):0.56 (d, J = 6.0 Hz, 3 H), 1.52-1.59 (m, 1H), 1.82-1.93 (m, 3H), 3.16-3.20 (m, 1H), 3.24-3.28 (m, 1H), 3.37-3.50 (m, 3H), 3.71-3.75 (m, 1H), 4.09-4.13 (m, 1H), 7.78 (d, J = 8.5 Hz, 1H), 8.37 (d, J = 6.5 Hz, 1H), 8.51 (d, J = 8.5 Hz, 1H), 8.54 (d, J = 6.0 Hz, 1H), 8.71 (s, 1H), 9.36 (s, 1H)
[α]25 D−95.3(c=0.035,H2O)
(R)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物38)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリンの合成
スペクトル(CDCl3, δ ppm):0.72 (d, J = 6.0 Hz, 3H), 1.45 (s, 9H), 1.80-1.86 (m, 1H), 1.93-1.98 (m, 2H), 2.15-2.17 (m, 1H), 2.82-2.95 (m, 3H), 3.17 -3.22 (m, 1H), 3.36-3.46 (m, 1H), 3.70-3.73 (m, 1H), 4.05-4.13 (m, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.37 (s, 1H)
(R)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物38)の合成
1H-NMRスペクトル(D2O, δ ppm):0.58 (d, J = 6.5 Hz, 3H), 1.87-1.99 (m, 3H), 2.10-2.20 (m, 1H), 3.13-3.17 (m, 2H), 3.29-3.30 (m, 3H), 3.64-3.69 (m, 1H), 4.11-4.15 (m, 1H), 8.18 (d, J = 6.0 Hz, 1H), 8.36 (d, J = 6.0 Hz, 1H), 8.49 (d, J = 9.5 Hz, 1H), 8.54 (br s, 1H), 8.68 (s, 1H), 9.61 (s, 1H)
[α]25 D−65.9(c=0.033,H2O)
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)−5−ニトロイソキノリン二塩酸塩(化合物39)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)−5−ニトロイソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.86 (d, J = 6.7 Hz, 1.5H), 0.94 (d, J = 6.7 Hz, 1.5H), 1.48 (s, 9H), 1.74-1.80 (m, 2H), 1.90-2.00 (m, 2H), 3.14-3.23 (m, 1H), 3.39-3.51 (m, 4H), 3.90-3.95 (m, 1H), 4.06 (s, 1H), 8.03 (t, J = 7.0 Hz, 1H), 8.21 (d, J = 5.5 Hz, 1H), 8.31 (d, J = 8.5 Hz, 1H), 8.75 (d, J = 5.5 Hz, 1H), 9.36 (s, 1H)
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)−5−ニトロイソキノリン二塩酸塩(化合物39)の合成
1H-NMRスペクトル (D2O, δ ppm):0.68 (d, J = 6.1 Hz, 3H), 1.77-1.82 (m, 1H), 1.84-1.91 (m, 2H), 1.94-2.02 (m, 1H), 3.20-3.26 (m, 3H), 3.35-3.40 (m, 1H), 3.49 (dd, J = 5.8, 13.1 Hz, 1H), 4.02 (dd, J = 9.2, 15.9 Hz, 1H), 4.14-4.22 (m, 1H), 8.37-8.41 (m, 2H), 8.61-8.64 (m, 2H), 9.56-9.63 (m, 1H)
[α]25 D+65.9(c=0.064,H2O)
(2R, 6R)−6−(2, 6−ジメチルピペラジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物40)の合成
(2R, 6R)−6−(4−tert−ブトキシカルボニル−2, 6−ジメチルピペラジン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm): 1.25 (s, 6H), 1.45 (s, 9H), 3.23 (br s, 1H), 3.45 (br s, 2H), 3.62 (br s, 1H), 4.07-4.17 (m, 2H), 7.77 (d, J = 6.0 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 9.5 Hz, 1H), 8.39 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.35 (s, 1H)
(2R, 6R)−6−(2, 6−ジメチルピペラジン−1−イルスルホニル)イソキノリン二塩酸塩(化合物40)の合成
1H-NMRスペクトル(D2O, δ ppm): 1.23 (d, J = 7.0 Hz, 6H), 3.08-3.12 (m, 2H), 3.26-3.29 (m, 2H), 4.34 (br s, 2H), 8.17 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 5.5 Hz, 1H), 8.50 (d, J = 8.5 Hz, 1H), 8.55 (br s, 1H), 8.70 (s, 1H), 9.36 (s, 1H)
[α]25 D−38.2(c=0.038,H2O)
(2S, 7S)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物41)の合成
(2S, 7S)−6−(4−tert−ブトキシカルボニル−2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm): 1.12 (d, J = 6.0 Hz, 3H), 1.26 (d, J = 6.0 Hz, 3H), 1.48 (s, 9H), 1.62 (br s, 2H), 3.46-3.69 (m, 4H), 4.11-4.18 (m, 2H), 7.77 (d, J = 6.0 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.38 (s, 1H), 8.67 (d, J = 6.0 Hz, 1H), 9.34 (s, 1H)
(2S, 7S)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物41)の合成
1H-NMRスペクトル(D2O, δ ppm): 0.90 (d, J = 6.5 Hz, 3H), 1.33 (d, J = 6.5 Hz, 3H), 1.70-1.78 (m, 1H), 2.26-2.32 (m, 1H), 3.18-3.27 (m, 2H), 3.38-3.44 (m, 2H), 3.82-3.84 (m, 1H), 4.19-4.23 (m, 1H), 8.04 (d, J = 8.5 Hz, 1H), 8.13 (br s, 1H), 8.31 (d, J = 8.5 Hz, 1H), 8.51 (m, 2H), 9.66 (s, 1H)
(S)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物42)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm): 0.72 (d, J = 7.0 Hz, 3H), 1.45 (s, 9H), 1.80-1.98 (m, 2H), 2.15-2.20 (m, 2H), 2.82-3.00 (m, 2H), 3.17-3.25 (m, 1H), 3.38-3.45 (m, 1H), 3.63-3.73 (m, 2H), 4.06-4.13 (m, 1H), 7.78 (d, J = 5.0 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.37 (s, 1H)
(S)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物42)の合成
1H-NMRスペクトル(D2O, δ ppm): 0.59 (d, J = 6.0 Hz, 3H), 1.85-2.00 (m, 3H), 2.15-2.19 (m, 1H), 3.14-3.22 (m, 2H), 3.30-3.34 (m, 3H), 3.65-3.70 (m, 1H), 4.11-4.15 (m, 1H), 8.17 (d, J = 9.0 Hz, 1H), 8.34 (d, J = 5.5 Hz, 1H), 8.48 (d, J = 9.0 Hz, 1H), 8.54 (s, 1H), 8.67 (s, 1H), 9.62 (s, 1H)
[α]25 D+47.9(c=0.035,H2O)
(R)−6−(5−メチル−1,4, 7−オキサジアゾナン−4−イルスルホニル)イソキノリン二塩酸塩(化合物43)の合成
(R)−6−(7−tert−ブトキシカルボニル−5−メチル−1,4, 7−オキサジアゾナン−4−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル(CDCl3, δ ppm): 0.59 (d, J = 7.0 Hz, 3H), 1.51 (s, 9H), 3.03-3.18 (m, 3H), 3.33-3.39 (m, 2H), 3.50-3.53 (m, 1H), 3.81-3.98 (m, 3H), 4.07-4.14 (m, 1H), 4.69 (br s, 1H), 7.78 (d, J = 6.0 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.36 (s, 1H), 8.67 (d, J = 8.5 Hz, 1H), 9.36 (s, 1H)
(R)−6−(5−メチル−1,4, 7−オキサジアゾナン−4−イルスルホニル)イソキノリン二塩酸塩(化合物43)の合成
1H-NMRスペクトル(D2O, δ ppm): 0.58 (d, J = 7.0 Hz, 3H) , 3.17 (dd, J = 3.2, 14 Hz, 3H), 3.48-3.55 (m, 2H), 3.72-3.77 (m, 2H), 3.81-3.84 (m, 1H), 3.97 (d, J = 12.5 Hz, 1H), 4.12-4.17 (m, 1H), 4.45-4.55 (m, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.38 (d, J = 6.0 Hz, 1H), 8.52 (d, J = 8.5 Hz, 1H), 8.56 (d, J = 6.0 Hz, 1H), 8.72 (s, 1H), 9.36 (s, 1H)
[α]25 D−38.1(c=0.035,H2O)
(R)−6−(2−メチル−1,4,7−トリアゾナン−1−イルスルホニル)イソキノリン三塩酸塩(化合物44)の合成
(R)−6−(4、7−ジ−tert−ブトキシカルボニル−2−メチル−1,4,7−トリアゾナン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.52-0.67 (br m, 3H), 1.46 (dd, J = 8.2, 13.1 Hz, 9H), 1.56 (s, 9H), 3.06 (br s, 2H), 3.28-3.50 (m, 5H), 3.56 (d, J = 14.0 Hz, 1H), 3.84 (d, J = 11.6 Hz, 1H), 4.00 (d, J = 13.1 Hz, 1H), 4.73 (s, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 8.13 (dd, J = 8.9, 13.1 Hz, 1H), 8.37 (d, J = 16.5 Hz, 1H), 8.69 (t, J = 6.1 Hz, 1H), 9.37 (d, J = 6.7 Hz, 1H)
(R)−6−(2−メチル−1,4,7−トリアゾナン−1−イルスルホニル)イソキノリン三塩酸塩(化合物44)の合成
1H-NMRスペクトル (D2O, δ ppm):0.60 (d, J = 4.9 Hz, 3H), 3.14 (t, J = 12.8 Hz, 1H), 3.40-3.51 (m, 4H), 3.63-3.68 (m, 2H), 3.71-3.77 (m, 2H), 3.84 (t, J = 11.6 Hz, 1H), 4.54-4.59 (m, 1H), 8.28 (d, J = 8.5 Hz, 1H), 8.48 (d, J = 6.7 Hz, 1H), 8.58 (d, J = 6.1 Hz, 1H), 8.61 (d, J = 8.5 Hz, 1H), 8.81 (s, 1H), 9.71 (s, 1H)
[α]25 D−59.0(c=0.040,H2O)
6−(4−グリシル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物45)の合成
6−(4−tert−ブトキシカルボニルグリシル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.42 (s, 9H), 2.02-2.04 (m, 2H), 2.56 (br s, 1H), 3.25-3.46 (m, 4H), 3.46-3.59 (m, 2H), 3.59-3.77 (m, 2H), 3.88-3.90 (m, 2H), 7.78 (d, J = 5.0 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.34 (s, 1H), 8.69 (d, J = 5.0 Hz, 1H), 9.37 (s, 1H)
6−(4−グリシル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物45)の合成
1H-NMRスペクトル (D2O, δ ppm):1.99-2.03 (m, 2H), 3.27 (t, J= 6.1 Hz, 2H), 3.30-3.31 (m, 2H), 3.46 (t, J = 6.1 Hz, 2H), 3.60 (t, J= 5.5 Hz, 2H), 4.01-4.05 (m, 2H), 8.14-8.15 (m, 1H), 8.41-8.46 (m, 1H), 8.53 (d, J = 6.7 Hz, 2H), 8.61 (s, 1H), 9.62-9.65 (m, 1H)
融点:吸湿性により測定不可
(S)−6−(4−グリシル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物46)の合成
(S)−6−(4−tert−ブトキシカルボニルグリシル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.12 (d, J = 7.0 Hz, 3H), 1.45 (s, 9H) 1.60-1.70 (m, 2H), 2.24 (br s, 1H), 2.79-2.84 (m, 1H), 3.02-3.21 (m, 3H), 3.51-3.53 (m, 1H), 3.80-3.83 (m, 1H), 4.11-4.15 (m, 2H), 4.45-4.53 (m, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.88 (d, J= 8.5 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 8.36 (s, 1H), 8.68 (d, J= 5.5 Hz, 1H), 9.33 (s, 1H)
(S)−6−(4−グリシル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩(化合物46)の合成
1H-NMRスペクトル (D2O, δ ppm):0.96 (d, J = 6.0 Hz, 3H), 1.75-1.90 (m, 2H), 3.23-3.31 (m, 5H), 3.50-3.57 (m, 2H), 4.05-4.40 (m, 2H), 7.98-8.28 (m, 2H), 8.41 (d, J = 7.5 Hz, 1H), 8.58 (s, 1H), 8.78 (s, 1H), 9.68 (s, 1H)
融点:190〜191度
(R)−6−(4−グリシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物47)の合成
(R)−6−(4−tert−ブトキシカルボニルグリシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.85 (d, J = 6.7 Hz, 3H), 1.47 (s, 9H), 1.52 (m, 4H), 3.03-3.06 (m, 2H), 3.21-3.28 (m, 2H), 3.49 (ddd, J = 2.4, 7.9, 14.1 Hz, 1H), 3.65 (dd, J = 3.7, 17.1 Hz, 1H), 3.77-3.82 (m, 1H), 3.94-4.00 (m, 1H), 4.37-4.40 (m, 1H), 5.40 (s, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.89 (dd, J = 1.8, 8.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.36 (s, 1H), 8.68 (d, J = 5.5 Hz, 1H), 9.34 (s, 1H)
(R)−6−(4−グリシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物47)の合成
1H-NMRスペクトル (D2O, δ ppm):0.62 (d, J = 6.8 Hz, 3H), 1.78-1.93 (m, 4H), 3.02 (dd, J = 11.2, 15.5 Hz, 1H), 3.07-3.13 (m, 1H), 3.20 (dd, J = 7.7, 14.7 Hz, 1H), 3.55-3.69 (m, 2H), 3.76 (dd, J = 5.6, 14.4 Hz, 1H), 3.97 (d, J = 16.6 Hz, 1H), 4.06 (d, J = 16.6 Hz, 1H), 4.29-4.36 (m, 1H), 8.20 (d, J = 8.2 Hz, 1H), 8.44 (d, J = 5.0 Hz, 1H), 8.55 (d, J = 8.8 Hz, 1H), 8.58 (d, J = 6.6 Hz, 1H), 8.68 (s, 1H), 9.66 (s, 1H)
[α]23 D−36.3(c=0.042,H2O)
(R)−6−(4−サルコシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物48)の合成
(R)−6−(4−tert−ブトキシカルボニルサルコシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.75 (d, J = 6.1 Hz, 3H), 1.46 (s, 9H), 1.63 (s, 1H), 1.72-1.86 (m, 2H), 2.09 (s, 1H), 2.42 (s, 3H), 3.01-3.08 (m, 2H), 3.13 (s, 1H), 3.33 (s, 1H), 3.59-3.73 (m, 2H), 3.80 (d, J = 14.0 Hz, 1H), 4.21 (s, 1H), 4.36 (s, 1H), 7.75 (d, J = 4.9 Hz, 1H), 7.90 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 8.34 (s, 1H), 8.66 (s, 1H), 9.34 (s, 1H)
(R)−6−(4−サルコシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン二塩酸塩(化合物48)の合成
1H-NMRスペクトル (D2O, δ ppm):0.57 (d, J = 6.7 Hz, 3H), 1.64-1.90 (m, 4H), 2.72 (s, 3H), 2.97 (t, J = 13.7 Hz, 1H), 3.03-3.18 (m, 2H), 3.51-3.62 (m, 2H), 3.73 (dd, J = 4.3, 14.0 Hz, 1H), 4.02 (d, J = 15.9 Hz, 1H), 4.11 (d, J = 16.5 Hz, 1H), 4.27-4.32 (m, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.45 (d, J = 6.7 Hz, 1H), 8.54 (d, J = 5.5 Hz, 2H), 8.66 (s, 1H), 9.60 (s, 1H)
[α]25 D−12.4(c=0.055,H2O)
(S)−5−メチル−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン(化合物49)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)−5−メチルイソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.95 (d, J = 6.4 Hz, 1.5H), 0.99 (d, J = 6.4 Hz, 1.5H), 1.48 (s, 4.5H), 1.50 (s, 4.5H), 1.62 (s, 1H), 1.75-1.86 (m, 1H), 2.94 (s, 3H), 3.03-3.20 (m, 2H), 3.70-3.92 (m, 4H), 4.27 (d, J = 6.5 Hz, 0.5H), 4.28 (d, J = 6.5 Hz, 0.5H), 7.94 (d, J = 7.6 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 8.18 (t, J = 7.9 Hz, 1H), 8.67 (d, J = 6.1 Hz, 1H), 9.31 (s, 1H)
(S)−5−メチル−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン(化合物49)の合成
1H-NMRスペクトル (D2O, δ ppm):0.85 (d, J = 6.7 Hz, 3H), 2.03 (s, 2H), 2.94 (s, 3H), 3.07-3.13 (m, 2H), 3.43 (td, J = 4.7, 9.0 Hz, 1H), 3.48-3.55 (m, 2H), 3.88 (d, J = 4.4 Hz, 0.5H), 3.89 (d, J = 4.4 Hz, 0.5H), 4.31 (d, J = 5.4 Hz, 0.5H), 4.32 (d, J = 5.4 Hz, 0.5H), 8.20 (d, J = 9.2 Hz, 1H), 8.32 (d, J = 9.2 Hz, 1H), 8.53 (d, J = 6.7 Hz, 1H), 8.63 (d, J = 6.7 Hz, 1H), 9.59 (s, 1H)
融点:225度
(S)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン三塩酸塩(化合物50)の合成
(S)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン 2−オキシドの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.02 (d, J = 6.0 Hz, 3H), 1.43 (s, 9H), 1.50-1.60 (m, 2H), 3.04-3.11 (m, 3H), 3.68-3.92 (m, 3H), 4.35-4.45 (m, 1H), 7.75-7.81 (m, 2H), 7.89 (dd, J = 1.5, 7.0 Hz, 1H), 8.22 (dd, J = 1.5, 7.0 Hz, 1H), 8.31 (s, 1H), 8.78 (s, 1H)
(S)−1−{2−(tert−ブトキシカルボニルアミノ)エチルチオ}−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.88-0.98 (m, 3H), 1.39 (s, 9H), 1.45 (s, 9H), 1.67-1.72 (m, 2H), 3.08-3.15 (m, 3H), 3.50-3.54 (m, 4H), 3.60-3.68 (m, 2H), 3.81-3.92 (m, 2H), 4.38-4.42 (m, 1H), 7.43 (d, J = 5.5 Hz, 1H), 7.85 (d, J= 9.0 Hz, 1H), 8.27-8.29 (m, 2H), 8.38 (d, J = 5.5 Hz, 1H)
(S)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン三塩酸塩(化合物50)の合成
1H-NMRスペクトル (D2O, δ ppm):0.96 (d, J = 7.0 Hz, 3H), 1.80-1.90 (m, 2H), 2.93-3.05 (m, 2H), 3.15-3.19 (m, 3H), 3.31-3.43 (m, 2H), 3.59 (t, J = 7.0 Hz, 2H), 3.68-3.71 (m, 1H), 4.40-4.45 (m, 1H), 7.87 (d, J = 6.0 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.30 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 6.0 Hz, 1H), 8.62 (s, 1H)
融点:174〜175度
[α]25 D+46.4(c=0.034,H2O)
(R)−1−(2−アミノエチルチオ)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン三塩酸塩(化合物51)の合成
(R)−6−(4−tert−ブトキシカルボニル−7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン 2−オキシドの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.02 (d, J = 6.7 Hz, 3H), 1.44 (s, 9H), 1.62 (s, 1H), 2.12 (s, 1H), 3.18-3.33 (m, 3H), 3.62-3.93 (m, 3H), 4.21 (dd, J = 6.7, 13.4 Hz, 1H), 7.80 (d, J = 7.3 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 8.23 (d, J = 7.3 Hz, 1H), 8.32 (s, 1H), 8.80 (s, 1H)
(R)−1−{2−(tert−ブトキシカルボニルアミノ)エチルチオ}−6−(4−tert−ブトキシカルボニル−7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.99 (d, J = 6.7 Hz, 3H), 1.28-1.29 (m, 1H), 1.43 (s, 18H), 2.11 (s, 1H), 3.18-3.28 (m, 2H), 3.53 (s, 4H), 3.71-3.78 (m, 2H), 3.85 (d, J = 11.0 Hz, 1H), 3.94 (s, 1H), 4.22 (s, 1H), 5.18 (s, 1H), 7.44 (d, J = 5.5 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 8.28 (s, 1H), 8.31 (d, J = 8.5 Hz, 1H), 8.40 (d, J = 5.5 Hz, 1H)
(R)−1−(2−アミノエチルチオ)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン三塩酸塩(化合物51)の合成
1H-NMRスペクトル (D2O, δ ppm):0.76 (d, J = 6.7 Hz, 3H), 1.63 (dt, J = 8.4, 18.7 Hz, 1H), 2.29 (dt, J = 7.6, 12.3 Hz, 1H), 2.99-3.04 (m, 2H), 3.32 (t, J = 6.1 Hz, 2H), 3.35-3.40 (m, 3H), 3.55 (t, J = 6.1 Hz, 2H), 3.93 (d, J = 16.5 Hz, 1H), 4.14-4.16 (m, 1H), 7.61 (d, J = 5.5 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 8.32 (dd, J = 1.2, 5.5 Hz, 1H), 8.35 (d, J = 8.5 Hz, 1H), 8.41 (s, 1H)
融点:187度
[α]25 D−70.2(c=0.032,H2O)
(R)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン三塩酸塩(化合物52)の合成
(R)−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン 2−オキシドの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.84 (d, J = 6.7 Hz, 1.5H), 0.94 (d, J = 6.7 Hz, 1.5H), 1.47 (s, 9H), 1.65-1.74 (m, 4H), 3.03-3.08 (m, 1H), 3.28-3.60 (m, 5H), 4.21-4.27 (m, 1H), 7.80 (dd, J = 7.9, 16.5 Hz, 2H), 7.91 (d, J = 8.5 Hz, 1H), 8.22 (d, J = 7.3 Hz, 1H), 8.30 (s, 1H), 8.80 (s, 1H)
(R)−1−{2−(tert−ブトキシカルボニルアミノ)エチルチオ}−6−(4−tert−ブトキシカルボニル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):0.84 (d, J = 6.7 Hz, 1.5H), 0.87 (d, J = 6.7 Hz, 1.5H), 1.42 (s, 9H), 1.46 (s, 9H), 1.66-1.75 (m, 2H), 1.87-2.01 (m, 2H), 2.97-3.07 (m, 1H), 3.35-3.58 (m, 8H), 4.21-4.35 (m, 2H), 5.19 (s, 1H), 7.45 (d, J = 5.5 Hz, 1H), 7.86 (d, J = 8.9 Hz, 1H), 8.27 (s, 1H), 8.30 (d, J = 8.5 Hz, 1H), 8.40 (d, J = 5.5 Hz, 1H)
(R)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン三塩酸塩(化合物52)の合成
1H-NMRスペクトル (D2O, δ ppm):0.60 (d, J = 6.1 Hz, 3H), 1.71-1.73 (m, 1H), 1.79-1.89 (m, 2H), 1.96-2.00 (m, 1H), 3.13-3.21 (m, 4H), 3.32 (t, J = 6.1 Hz, 2H), 3.41 (dd, J = 7.3, 13.4 Hz, 1H), 3.56 (t, J = 6.1 Hz, 2H), 3.61-3.64 (m, 1H), 4.31-4.36 (m, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 8.33-8.35 (m, 2H), 8.42 (s, 1H)
融点:209〜213度
[α]23 D−35.9(c=0.040,H2O)
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン−1(2H)−オン 二塩酸塩(化合物53)の合成
6−(4−tert−ブトキシカルボニル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン 2−オキシドの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.41 (s, 9H), 1.93-2.04 (m, 2H), 3.29-3.40 (m, 4H), 3.48-3.59 (m, 4H), 7.78 (d, J = 7.0 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 8.22 (d, J = 7.0 Hz, 1H), 8.27 (s, 1H), 8.78 (s, 1H)
6−(4−tert−ブトキシカルボニル−1,4−ジアゼパン−1−イルスルホニル)−1−メトキシイソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.41 (s, 9H), 1.94-1.96 (m, 2H), 3.29-3.37 (m, 4H), 3.47-3.57 (m, 4H), 4.15 (s, 3H), 7.30 (d, J = 6.0 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 6.0 Hz, 1H), 8.21 (s, 1H), 8.37 (d, J = 8.5 Hz, 1H)
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン−1(2H)−オン(化合物53)の合成
1H-NMRスペクトル (DMSO-d6, δ ppm):1.95-1.99 (m, 2H), 2.01 (br s, 1H), 3.13-3.17 (m, 4H), 3.34-3.36 (m, 2H), 3.54-3.60 (m, 2H), 6.74 (d, J = 7.0 Hz, 1H), 7.32 (dd, J = 7.0 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 8.17 (s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 8.65 (br s, 1H), 11.5 (s, 1H)
融点:266−267度
1−アミノ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩 (化合物54)の合成
1−アミノ−6−(4−tert−ブトキシカルボニル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.41 (s, 9H), 2.15-2.20 (m, 2H), 3.30-3.38 (m, 4H), 3.47-3.57 (m, 4H), 5.25 (s, 2H), 7.13 (d, J = 6.0 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 8.06 (d, J = 6.0 Hz, 1H), 8.18 (s, 1H)
1−アミノ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩 (化合物54)の合成
1H-NMRスペクトル (DMSO-d6, δ ppm):1.95-2.00 (m, 2H), 2.11 (br s, 1H), 3.15-3.18 (m, 4H), 3.36-3.41 (m, 2H), 3.55 (s, 2H), 3.60-3.64 (m, 2H), 7.40 (d, J = 7.0 Hz, 1H), 7.82 (d, J = 7.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.26 (br s, 2H), 8.47 (s, 1H), 8.86 (d, J = 8.0 Hz, 1H)
融点:214−215度
1−ニトリル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩 (化合物55)の合成
1−ニトリル−6−(4−tert−ブトキシカルボニル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.41 (s, 9H), 1.97 (br s, 2H), 3.38 (br s, 2H), 3.40 (br s, 2H), 3.50 (br s, 2H), 3.58 (br s, 2H), 8.03 (d, J = 6.0 Hz, 1H), 8.06 (d, J = 9.0 Hz, 1H), 8.45 (s, 1H), 8.49 (d, J = 9.0 Hz, 1H), 8.80 (d, J = 6.0 Hz, 1H)
1−ニトリル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩 (化合物55)の合成
1H-NMRスペクトル (D2O, δ ppm):2.11-2.13 (m, 2H), 3.36-3.42 (m, 4H), 3.48 (t. J = 6.0 Hz, 2H), 3.69 (t. J = 6.0 Hz, 2H), 8.11 (d, J = 8.5Hz, 1H), 8.27 (d, J = 6.0 Hz, 1H), 8.46 (d, J = 8.5Hz, 1H), 8.59 (s, 1H), 8.71 (d, J = 8.5 Hz, 1H)
(S)−6−{2−(4−アミノブチル)−1,4−ジアゼパン−1−イルスルホニル}イソキノリン三塩酸塩 (化合物56)の合成
(S)−6−{4−tert−ブトキシカルボニル−2−(4−tert−ブトキシカルボニルアミノブチル)−1,4−ジアゼパン−1−イルスルホニル}イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.11-1.27 (m, 2H), 1.35-1.37 (m, 2H), 1.46 (s, 9H), 1.40 (S, 9H), 1.70-2.05 (m, 4H), 2.87-3.03 (m, 3H), 3.30-3.65 (m, 4H), 3.81-3.88 (m, 1H), 4.09-4.21 (m, 1H), 4.60 (br s, 1H), 7.78 (d, J = 6.0 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.39 (s, 1H), 8.67 (d, J = 6.0 Hz, 1H), 9.35 (s, 1H)
(S)−6−{2−(4−アミノブチル)−1,4−ジアゼパン−1−イルスルホニル}イソキノリン三塩酸塩 (化合物56)の合成
1H-NMRスペクトル (D2O, δ ppm):1.04-1.14 (m, 2H), 1.31-1.48 (m, 3H), 1.56-1.61 (m, 1H), 1.83-1.93 (m, 2H), 2.48-2.50 (m, 2H), 3.03-3.07 (m, 2H), 3.25-3.32 (m, 3H), 3.75-3.80 (m, 1H), 4.30-4.32 (m, 1H), 7.90 (m, 2H), 8.17 (d, J = 8.5 Hz, 1H), 8.31 (s, 1H), 8.49 (d, J = 8.5 Hz, 1H), 8.72 (s, 1H)
融点:38〜40度
[α]25 D−22.9(c=0.0483,H2O)
6−(4−メトキシカルボニルピペリジン−1−イルスルホニル)イソキノリン塩酸塩(化合物57)の合成
6−(4−メトキシカルボニルピペリジン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.80-1.87 (m, 2H), 1.96-2.00 (m, 2H), 2.27-2.31 (m, 1H), 2.61-2.66 (m, 2H), 3.64 (s, 3H), 3.69-3.72 (m, 2H),7.78 (d, J = 6.0 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.31 (s, 1H), 8.69 (d, J = 6.0 Hz, 1H), 9.38 (s, 1H)
6−(4−メトキシカルボニルピペリジン−1−イルスルホニル)イソキノリン塩酸塩の合成
1H-NMRスペクトル (D2O, δ ppm):1.61-1.69 (m, 2H), 1.94-1.97 (m, 2H), 2.39-2.43 (m, 1H), 2.68-2.73 (m, 2H), 3.60 (s, 3H), 3.74-3.77 (m, 2H),8.23 (d, J = 7.8 Hz, 1H), 8.58 (d, J = 7.8 Hz, 1H), 8.65-8.67 (m, 2H), 8.73 (s, 1H), 9.79 (s, 1H)
(S)−6−(3−ヒドロキシピロリジン−1−イルスルホニル)イソキノリン塩酸塩(化合物58)の合成
(S)−6−(3−ヒドロキシピロリジン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.95-2.01 (m, 2H), 3.34-3.43 (m, 1H), 3.44-3.55 (m, 3H), 4.42 (br s 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.98 (d, J = 9.0 Hz, 1H), 8.11 (d, J = 9.0 Hz, 1H), 8.38 (s, 1H), 8.65 (d, J = 5.5 Hz, 1H), 9.32 (s, 1H)
(S)−6−(3−ヒドロキシピロリジン−1−イルスルホニル)イソキノリン塩酸塩の合成
1H-NMRスペクトル (D2O, δ ppm):1.63-1.76 (m, 2H), 3.14 (d, J = 11.0 Hz, 1H), 3.26-3.40 (m, 3H), 4.13-4.14 (m, 1H), 8.14 (d, J = 9.0 Hz, 1H), 8.45 (d, J = 5.5 Hz, 1H), 8.54 (d, J = 9.0 Hz, 1H), 8.69 (s, 1H), 8.76 (br s, 1H), 9.80 (br s, 1H)
5−フェニル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩 (化合物59)の合成
5−フェニル−6−(4−tert−ブトキシカルボニル−1,4−ジアゼパン−1−イルスルホニル)イソキノリンの合成
1H-NMRスペクトル (CDCl3, δ ppm):1.43 (s, 9H), 1.75-1.79 (m, 2H), 2.66-2.77 (m, 4H), 3.35-3.46 (m, 4H), 7.12 (d, J = 6.0 Hz, 1H), 7.31-7.32 (m, 2H), 7.53-7.54 (m, 3H), 8.12 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 8.0 Hz, 1H), 8.47 (d, J = 6.0 Hz, 1H),9.36 (s, 1H)
5−フェニル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン二塩酸塩 (化合物59)の合成
1H-NMRスペクトル (D2O, δ ppm):1.85-1.90 (m, 2H), 2.95-2.99 (m, 4H), 3.09-3.11 (m, 2H), 3.20-3.24 (m, 2H), 7.33-7.35 (m, 2H), 7.50-7.54 (m, 3H), 7.70 (d, J = 6.0 Hz, 1H), 8.37 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 8.5Hz, 1H), 8.83 (d, J = 6.0 Hz, 1H),9.35 (s, 1H)
評価例1
本発明化合物のラットにおける血圧降下作用
ラット(SD、性別:雄性、1群6匹)に本発明化合物を腹腔内投与した際の血圧降下作用を評価した。被験化合物としては実施例18を使用した。
被験化合物を生理食塩水に溶解、希釈し、所定の濃度の被験化合物溶液を調製した。
ラット(1群6匹)に被験薬物を10mg/kgの用量で腹腔内に投与し、ソフトロン社製非観血血圧測定装置BP−98Aを用いて血圧と脈拍数を経時的に測定した。
本発明化合物を投与した動物の収縮期血圧は投与前値に比較して最大30%以上降下し、本発明化合物は優れた血圧降下作用を有することが明らかとなった。また同時に測定した脈拍数は増加し、これは血管拡張による血圧降下が生じその代償としての脈拍数増加と認められた。これらの結果から、本発明化合物は高血圧症を始めとする循環器疾患の治療剤として有用であることがわかった。
本発明化合物の高血圧自然発症ラットにおける血圧降下作用
高血圧自然発症ラット(SHR/Izm、性別:雄性、1群4〜6匹)に本発明化合物を腹腔内投与し血圧降下作用を評価した。被験化合物としては実施例32、34、35を使用した。
被験化合物を生理食塩水に溶解、希釈し、所定の濃度の被験化合物溶液を調製した。
動物(1群4〜6匹)に被験薬物を10mg/kg(実施例34のみ30mg/kg)の用量で腹腔内に投与し、ソフトロン社製非観血血圧測定装置BP−98Aを用いて血圧と脈拍数を経時的に測定した。
本発明化合物を投与した動物の収縮期血圧は投与前値に比較して最大で実施例34及び35は30%以上降下させた。実施例32は16%降下させた。このように本発明化合物は優れた血圧降下作用を有することが明らかとなった。また同時に測定した脈拍数は増加していた。これは、血管拡張による血圧降下が生じ、その代償としての脈拍数増加と認められた。これらの結果から、本発明化合物は高血圧症を始めとする循環器疾患の治療剤として有用であることがわかった。
本発明化合物のウサギにおける眼圧降下作用
ウサギ(ニュージーランド白色、性別:雄性、一群3〜7)に本発明化合物を投与した際の眼圧降下作用を評価した。
被験化合物を基剤(リン酸二水素ナトリウム二水和物1.04g、塩化ナトリウム0.5gを精製水に溶解し水酸化ナトリウムでpHを7.0に調製し全量を100mLにした)に溶解し、1%(W/V)の濃度の被験化合物溶液を調製した。
ウサギに被験化合物投与直前にティオラト社製トノベット手持眼圧計を用いて眼圧を測定した。片眼に被験化合物溶液を、対側眼に基剤のみをそれぞれ0.04mL点眼し、同様に眼圧を経時的に測定した。基剤投与眼の眼圧に対する被験化合物溶液投与眼の眼圧の割合を降下度として算出した。
各被験化合物の最大降下度を表1に示した。表1に示したように、本発明化合物はいずれも優れた眼圧降下作用を示した。このことから、本発明化合物は緑内障治療薬として有用であることがわかった。
神経細胞軸索伸展作用
本発明化合物の神経変性疾患治療剤としての有用性を調べるため、神経モデル細胞として多用されるNG108−15細胞を本発明化合物存在下で培養し、神経軸索伸展作用を評価した。被験化合物としては実施例15及び49を使用した。
被験化合物をジメチルスルホキシドに溶解、希釈し、所定の濃度の被験化合物溶液を調製した。
NG108−15細胞(ATCCより入手)は、5%ウシ胎児血清及び1×HAT(ヒポキサンチン、アミノプテリン、チミジン)を含有するダルベッコ変法イーグル培地で培養した。24ウェルプレートに12,000細胞/ウェルとなるように細胞を撒き、37℃、5%CO2、95%空気の環境下12時間の静置培養後、終濃度10,3,1,0.3μmol/Lとなるように被験化合物を添加した。その後24時間後に倒立顕微鏡下で神経軸索伸展の程度を観察した。
化合物添加培養液で培養したNG108−15細胞では化合物無添加で培養した細胞と比較して顕著な軸索伸展が認められた。本発明化合物は神経細胞の軸索伸展作用を有することがわかった。
本発明化合物のマウス脊髄損傷モデルにおける運動機能回復作用
本発明化合物の脊髄損傷治療剤としての有用性を調べるため、マウスの脊髄損傷モデルを作成し、脊髄損傷後の運動機能の回復作用を検討した。
被験化合物として実施例14を生理食塩水に溶解、希釈し、所定の濃度の被験化合物溶液を調製した。
論文(Acta Neuropathol. 100, 13-22(2000))に記載の方法に従い、C57BL/6Crマウス(雌、体重19g前後、1群6〜8匹)をハロタン吸入麻酔し、第8胸椎レベルの脊髄を20gの重りで5分間圧迫することによって脊髄損傷モデルを作製した。被験化合物は手術日から連続して1日1回7日間3mg/kgの用量を腹腔内に投与した。脊髄損傷モデル作製後1,4,7,10,14日後に、J. Neurosurg. 93(1 Suppl.), 94,101(2000)に記載の行動スコアを一部修正して神経障害の程度を評点した。行動スコアの詳細は次の通りである。
オープン−フィールド移動行動(0〜42点)
つま先の拡がり(0〜5点)
接地反応(0〜5点)
引っ込め反応(伸展刺激、痛み刺激、加圧刺激に対する反応それぞれで0−5点)
正姿勢反応(0〜5点)
このスコアによれば正常動物は0点、最も重篤な障害を持つ動物は72点となる。
術後14日目における各群の神経障害のスコアは、生理食塩水投与群が41点であったのに対し、被験化合物投与群は33点であった。本発明化合物は脊髄損傷後の運動機能の回復作用を示した。このことから本発明化合物は脊髄損傷の治療薬として有用であることがわかった。
Claims (8)
- 一般式(1)
R1及びR2はそれぞれ独立して水素原子、ハロゲン原子、シアノ基、アルキル基、ハロゲノアルキル基、アルケニル基、アルコキシ基、アルキルチオ基、ヒドロキシ基、メルカプト基、ニトロ基、アリール基、アミノ基又はアミノアルキルチオ基を示し;
R3及びR4はそれぞれ独立して水素原子、アルキル基、アルケニル基、アミノ基、アルキルアミノ基、ジアルキルアミノ基、ハロゲノアルキル基、アルカノイル基、アミノアルカノイル基、アルキルアミノアルカノイル基、アルコキシカルボニル基、ヒドロキシ基又はメルカプト基を示すか、あるいはR3とR4が一緒になってアルキレン基又はアルケニレン基を形成し、任意の位置へ2つの炭素間で架橋していてもよく;
l、m及びnは1〜4の数を示す。)
で表されるイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物。 - 一般式(1)において、
X、Yがそれぞれ独立して直接結合、NH、CH=CH、O又はSであり;R1及びR2がそれぞれ独立して水素原子、ハロゲン原子、シアノ基、C1−8アルキル基、ハロゲノC1−8アルキル基、C2−8アルケニル基、C1−8アルコキシ基、C1−8アルキルチオ基、ヒドロキシ基、メルカプト基、ニトロ基、フェニル基、アミノ基又はアミノC1−8アルキルチオ基であり;R3及びR4がそれぞれ独立して水素原子、C1−8アルキル基、C2−8アルケニル基、アミノ基、ハロゲノC1−8アルキル基、C1−8アルキルアミノ基、ジ−C1−8アルキルアミノ基、C2−8アルカノイル基、アミノC2−8アルカノイル基、C1−8アルコキシカルボニル基、ヒドロキシ基、又はメルカプト基であるか、あるいはR3とR4が一緒になって架橋C1−3のアルキレン基又はアルケニレン基を形成し;l及びmがそれぞれ独立して1〜3であり;nが2〜3である請求項1記載のイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物。 - 一般式(1)において、
Xが直接結合又はNHであり;Yが直接結合、NH、CH=CH、又はOであり;R1及びR2がそれぞれ独立して水素原子、ハロゲン原子、C1−8アルキル基、ニトロ基、シアノ基、ヒドロキシ基、ハロゲノC1−8アルキル基、フェニル基、又はアミノC1−8アルキルチオ基であり;R3及びR4が水素原子、C1−8アルキル基、アミノ基、C1−8アルキルアミノ基、又はハロゲノC1−8アルキル基、アミノC1−8アルカノイル基又はC1−8アルキルアミノ基又はC1−8アルカノイル基であるか、あるいはR3とR4が一緒になって架橋C1−3のアルキレン基を形成し;l及びmがそれぞれ独立して1〜3であり;nが2〜3である請求項1又は2記載のイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物。 - 一般式(1)において、
Xが直接結合又はNHであり;Yが直接結合、NH、CH=CH、又はOであり;R1及びR2がそれぞれ独立して水素原子、ハロゲン原子、ニトロ基、アミノアルキルチオ基、C1−6アルキル基、ハロゲノC1−6アルキル基であり;R3及びR4が水素原子、C1−6アルキル基又はハロゲノC1−6アルキル基、アミノ基、C1−8アルキルアミノ基、アミノC1−8アルカノイル基であるか、あるいはR3とR4が一緒になって架橋C1−3のアルキレン基を形成し;l及びmがそれぞれ独立して1〜3であり;nが2〜3である請求項1〜3のいずれか1項記載のイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物。 - 一般式(1)において、
Xが直接結合又はNHであり;Yが直接結合、CH=CH、又はOであり;R1及びR2がそれぞれ独立して水素原子、ハロゲン原子、アミノアルキルチオ基、C1−6アルキル基であり;R3及びR4が水素原子、C1−6アルキル基、ハロゲノC1−6アルキル基、又はアミノ基であるか、あるいはR3とR4が一緒になって架橋C1−3のアルキレン基を形成し;l及びmがそれぞれ独立して1〜3であり;nが2〜3である請求項1〜4のいずれか1項記載のイソキノリン−6−スルホンアミド誘導体、その塩又はそれらの溶媒和物。 - 6−(ピペラジン−1−イルスルホニル)イソキノリン、
(R)−6−(3−アミノピロリジン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(4−アミノピペリジン−1−イルスルホニル)イソキノリン、
5−ブロモ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゼパン−1−イルスルホニル)−8−フルオロイソキノリン、
6−{(1S,4S)−2,5−ジアザビシクロ[2.2.1]ヘプタン−2−イルスルホニル}イソキノリン、
(R,Z)−6−(2−メチル−2,3,4,5−テトラヒドロ−1,4−ジアゾシン−1(8H)−イルスルホニル)イソキノリン、
6−(モルホリン−1−イルスルホニル)イソキノリン、
(S)−6−{3−(N−メチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン、
(S)−6−{3−(N−ブチルアミノ)ピロリジン−1−イルスルホニル}イソキノリン、
(S)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチルピペラジン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(3−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−エチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−エチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
6−(2,2−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)−7−フルオロイソキノリン、
(S)−6−(2−フルオロメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−フルオロメチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン、
(R)−5−ブロモ−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(6−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(7−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゾナン−1−イルスルホニル)イソキノリン、
(R)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(2R,7R)−6−(2,7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(2S, 7R)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(8−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)−5−ニトロイソキノリン、
(2R, 6R)−6−(2, 6−ジメチルピペラジン−1−イルスルホニル)イソキノリン、
(2S, 7S)−6−(2, 7−ジメチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−メチル−1,5−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(5−メチル−1,4, 7−オキサジアゾナン−4−イルスルホニル)イソキノリン、
(R)−6−(2−メチル−1,4,7−トリアゾナン−1−イルスルホニル)イソキノリン、
6−(4−グリシル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(4−グリシル−2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−6−(4−グリシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(R)−6−(4−サルコシル−2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
(S)−5−メチル−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−1−(2−アミノエチルチオ)−6−(7−メチル−1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(R)−1−(2−アミノエチルチオ)−6−(2−メチル−1,4−ジアゾカン−1−イルスルホニル)イソキノリン、
6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン−1(2H)−オン、
1−アミノ−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
1−ニトリル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン、
(S)−6−(2−(4−アミノブチル)−1,4−ジアゼピン−1−イルスルホニル)イソキノリン、
6−(4−メトキシカルボニルピペリジン−1−イルスルホニル)イソキノリン、
(S)−6−(3−ヒドロキシピロリジン−1−イルスルホニル)イソキノリン、
5−フェニル−6−(1,4−ジアゼパン−1−イルスルホニル)イソキノリン
から成る群より選択される化合物、その塩又はその溶媒和物。 - 請求項1〜6のいずれか1項記載の化合物を含有する医薬組成物。
- 緑内障、循環器疾患、又は神経変性若しくは神経損傷に起因する疾患若しくは障害の予防治療薬である請求項1〜6のいずれか1項記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011519583A JP4915010B2 (ja) | 2009-06-19 | 2010-06-18 | 置換されたイソキノリン誘導体 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009146040 | 2009-06-19 | ||
JP2009146040 | 2009-06-19 | ||
PCT/JP2010/004101 WO2010146881A1 (ja) | 2009-06-19 | 2010-06-18 | 置換されたイソキノリン誘導体 |
JP2011519583A JP4915010B2 (ja) | 2009-06-19 | 2010-06-18 | 置換されたイソキノリン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4915010B2 true JP4915010B2 (ja) | 2012-04-11 |
JPWO2010146881A1 JPWO2010146881A1 (ja) | 2012-12-06 |
Family
ID=43356211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011519583A Active JP4915010B2 (ja) | 2009-06-19 | 2010-06-18 | 置換されたイソキノリン誘導体 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8951997B2 (ja) |
EP (1) | EP2444395B1 (ja) |
JP (1) | JP4915010B2 (ja) |
KR (1) | KR101732907B1 (ja) |
CN (1) | CN102448941B (ja) |
AU (1) | AU2010261206B2 (ja) |
BR (1) | BRPI1011683B8 (ja) |
CA (1) | CA2764124C (ja) |
CY (1) | CY1117157T1 (ja) |
DK (1) | DK2444395T3 (ja) |
EA (1) | EA019523B1 (ja) |
ES (1) | ES2560603T3 (ja) |
HR (1) | HRP20160096T1 (ja) |
HU (1) | HUE028684T2 (ja) |
MX (1) | MX2011013857A (ja) |
NZ (1) | NZ596615A (ja) |
PL (1) | PL2444395T3 (ja) |
TW (1) | TWI527798B (ja) |
WO (1) | WO2010146881A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
ES2672624T3 (es) | 2009-05-01 | 2018-06-15 | Aerie Pharmaceuticals, Inc. | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
KR101911324B1 (ko) | 2010-12-22 | 2018-10-25 | 가부시키가이샤 디. 웨스턴 세라퓨틱스 겡큐쇼 | 신규한 치환 이소퀴놀린 유도체 |
JP2013035802A (ja) * | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | 緑内障又は高眼圧症の予防又は治療剤 |
ES2852377T3 (es) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
EP3626245B1 (en) * | 2013-04-24 | 2021-05-05 | Kyushu University, National University Corporation | Therapeutic agent for eyeground disease |
CN105085478B (zh) * | 2014-04-28 | 2019-04-12 | 南京明德新药研发股份有限公司 | 异喹啉磺胺衍生物及其药物组合物和制药用途 |
CN105906609A (zh) * | 2016-05-19 | 2016-08-31 | 武昌理工学院 | 一种1,4-二氮杂环庚烷衍生物的制备方法 |
JP7032814B2 (ja) | 2016-08-31 | 2022-03-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | オキソピコリンアミド誘導体、その製造方法およびその医薬用途 |
MX2019002396A (es) | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
US9840468B1 (en) | 2016-12-30 | 2017-12-12 | Aerie Pharmaceuticals, Inc. | Methods for the preparation of 6-aminoisoquinoline |
SG11201908179UA (en) | 2017-03-31 | 2019-10-30 | Aerie Pharmaceuticals Inc | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN109134433B (zh) * | 2017-06-16 | 2021-05-25 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其应用 |
CN108929270B (zh) * | 2018-08-15 | 2021-06-08 | 上海罕道医药科技有限公司 | 一种药物中间体双取代含氮杂环的胺类化合物的合成 |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
EP3875449A4 (en) * | 2018-11-01 | 2022-07-06 | D. Western Therapeutics Institute, Inc. | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF |
CN113194949A (zh) * | 2018-12-18 | 2021-07-30 | 株式会社D.西医疗法研究所 | 异喹啉磺酰氯酸加成盐和其制造方法 |
WO2022047315A1 (en) * | 2020-08-31 | 2022-03-03 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080394A1 (en) * | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
US20060079556A1 (en) * | 2004-10-12 | 2006-04-13 | Sher Philip M | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
WO2006073448A2 (en) * | 2004-04-27 | 2006-07-13 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20080064681A1 (en) * | 2006-09-11 | 2008-03-13 | Hiroyoshi Hidaka | Therapeutic agent for treating glaucoma |
WO2008105442A1 (ja) * | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド誘導体 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
JPS5993054A (ja) | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
US4678783B1 (en) | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
JPH0667926B2 (ja) | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
JPH0215067A (ja) | 1988-07-04 | 1990-01-18 | Hokuriku Seiyaku Co Ltd | イソキノリンスルホンアミド誘導体 |
US5216150A (en) | 1988-12-26 | 1993-06-01 | Hiroyoshi Hidaka | Derivatives of isoquinoline (and naphthalene) sulfonamides |
US5245034A (en) | 1988-12-26 | 1993-09-14 | Kiroyoshi Hidaka | Compound having vessel smooth muscle relaxation activity |
JPH069402A (ja) | 1991-05-15 | 1994-01-18 | Hiroyoshi Hidaka | 抗潰瘍剤 |
AU1557497A (en) | 1996-02-02 | 1997-08-22 | Nippon Shinyaku Co. Ltd. | Isoquinoline derivatives and drugs |
CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
WO2006115244A1 (ja) | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | 4-ブロモイソキノリン誘導体及びこれを含有する医薬 |
DE602006005351D1 (de) | 2005-04-25 | 2009-04-09 | Western Therapeutics Inst Inc | Hochselektiver rho-kinase-inhibitor |
WO2007026664A1 (ja) | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
AU2007338410B2 (en) | 2006-12-27 | 2012-08-16 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
KR20090103903A (ko) | 2006-12-27 | 2009-10-01 | 사노피-아벤티스 | 사이클로알킬아민 치환된 이소퀴놀론 및 이소퀴놀리논 유도체 |
-
2010
- 2010-06-18 TW TW099120004A patent/TWI527798B/zh active
- 2010-06-18 BR BRPI1011683A patent/BRPI1011683B8/pt active IP Right Grant
- 2010-06-18 MX MX2011013857A patent/MX2011013857A/es active IP Right Grant
- 2010-06-18 DK DK10789260.6T patent/DK2444395T3/en active
- 2010-06-18 NZ NZ596615A patent/NZ596615A/xx unknown
- 2010-06-18 JP JP2011519583A patent/JP4915010B2/ja active Active
- 2010-06-18 AU AU2010261206A patent/AU2010261206B2/en active Active
- 2010-06-18 KR KR1020117028931A patent/KR101732907B1/ko active IP Right Grant
- 2010-06-18 EP EP10789260.6A patent/EP2444395B1/en active Active
- 2010-06-18 WO PCT/JP2010/004101 patent/WO2010146881A1/ja active Application Filing
- 2010-06-18 ES ES10789260.6T patent/ES2560603T3/es active Active
- 2010-06-18 CN CN201080023516.8A patent/CN102448941B/zh active Active
- 2010-06-18 US US13/265,246 patent/US8951997B2/en active Active
- 2010-06-18 CA CA2764124A patent/CA2764124C/en active Active
- 2010-06-18 HU HUE10789260A patent/HUE028684T2/en unknown
- 2010-06-18 EA EA201171328A patent/EA019523B1/ru unknown
- 2010-06-18 PL PL10789260T patent/PL2444395T3/pl unknown
-
2016
- 2016-01-21 CY CY20161100066T patent/CY1117157T1/el unknown
- 2016-01-28 HR HRP20160096TT patent/HRP20160096T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080394A1 (en) * | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
WO2006073448A2 (en) * | 2004-04-27 | 2006-07-13 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060079556A1 (en) * | 2004-10-12 | 2006-04-13 | Sher Philip M | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
US20080064681A1 (en) * | 2006-09-11 | 2008-03-13 | Hiroyoshi Hidaka | Therapeutic agent for treating glaucoma |
WO2008105442A1 (ja) * | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド誘導体 |
Also Published As
Publication number | Publication date |
---|---|
CY1117157T1 (el) | 2017-04-05 |
WO2010146881A1 (ja) | 2010-12-23 |
EP2444395A4 (en) | 2012-11-28 |
PL2444395T3 (pl) | 2016-06-30 |
CN102448941B (zh) | 2016-04-06 |
MX2011013857A (es) | 2012-01-30 |
ES2560603T3 (es) | 2016-02-22 |
AU2010261206B2 (en) | 2015-10-08 |
EP2444395B1 (en) | 2016-01-06 |
AU2010261206A1 (en) | 2011-12-15 |
EA019523B1 (ru) | 2014-04-30 |
BRPI1011683A2 (pt) | 2016-03-22 |
HUE028684T2 (en) | 2016-12-28 |
NZ596615A (en) | 2013-07-26 |
TW201100385A (en) | 2011-01-01 |
EA201171328A1 (ru) | 2012-05-30 |
KR101732907B1 (ko) | 2017-05-08 |
CN102448941A (zh) | 2012-05-09 |
BRPI1011683B8 (pt) | 2021-05-25 |
US20120035159A1 (en) | 2012-02-09 |
TWI527798B (zh) | 2016-04-01 |
JPWO2010146881A1 (ja) | 2012-12-06 |
HRP20160096T1 (hr) | 2016-02-26 |
DK2444395T3 (en) | 2016-03-14 |
EP2444395A1 (en) | 2012-04-25 |
CA2764124C (en) | 2016-12-13 |
US8951997B2 (en) | 2015-02-10 |
KR20120069609A (ko) | 2012-06-28 |
CA2764124A1 (en) | 2010-12-23 |
BRPI1011683B1 (pt) | 2020-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4915010B2 (ja) | 置換されたイソキノリン誘導体 | |
JP4124805B1 (ja) | オキシトシンアンタゴニストとしての置換トリアゾール誘導体 | |
JP7297776B2 (ja) | ピペリジニル-3-(アリールオキシ)プロパンアミド及びプロパノエート | |
RU2720203C1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl | |
TW202115062A (zh) | Kras突變蛋白抑制劑 | |
EP3310773B1 (en) | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | |
JP5781093B2 (ja) | 新たな置換イソキノリン誘導体 | |
AU2013209586A1 (en) | Substituted pyrimidine compounds and their use as SYK inhibitors | |
US20150320763A1 (en) | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | |
CA3226724A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
WO2004022535A1 (ja) | アクリルアミド誘導体 | |
CN100381446C (zh) | 氨基甲基取代的噻唑并苯并咪唑衍生物 | |
WO2021202775A1 (en) | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists | |
JP2023526840A (ja) | ピペラジン複素環アミド尿素類を含む受容体共役タンパク質1阻害剤 | |
WO2023059583A1 (en) | Heterobifunctional compounds and their use in treating disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111220 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120105 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150203 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4915010 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |